TrialID,"Last Refreshed on","Public title","Scientific title",Acronym,"Primary sponsor","Date registration","Date registration3","Export date","Source Register","web address","Recruitment Status","other records","Inclusion agemin","Inclusion agemax","Inclusion gender","Date enrollement","Target size","Study type","Study design",Phase,Countries,"Contact Firstname","Contact Lastname","Contact Address","Contact Email","Contact Tel","Contact Affiliation","Inclusion Criteria","Exclusion Criteria",Condition,Intervention,"Primary outcome","Secondary outcome","Secondary ID","Source Name","Secondary Sponsor","Ethics Status","Ethics Approval Date","Ethics Contact Name","Ethics Contact Address","Ethics Contact Phone","Ethics Contact Email","results yes no","results date posted","results url link","results url protocol","results date completed","results date first publication","results summary","results baseline char","results adverse events","results outcome measures","results ipd plan","results ipd description","Prospective registration","Bridging flag truefalse","Bridged type"
NCT06356974,"15 April 2024","Stop Transmission of Gambiense Human African Trypanosomiasis (STROgHAT)","An Intervention Study to Evaluate the Impact of Treating gHAT Seropositive Subjects With Acoziborole on Transmission of T.b. Gambiense, and Obtain Further Safety Data on Acoziborole in gHAT Seropositive Individuals",STROgHAT,"Drugs for Neglected Diseases",29/03/2024,"  20240329","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT06356974,"Not recruiting",No,"11 Years",N/A,All,08/04/2024,2500,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3",," ; ","Elena Nicco, MD;Elena Nicco, MD",,;enicco@itg.be,;+3232476497,"Institute of Tropical Medicine;","<br>    Inclusion Criteria:<br><br>     - • Participants able to give signed informed consent and assent form for adolescents,<br>       which includes willingness to comply with the schedule of follow-up visits and other<br>       requirements and restrictions listed in the informed consent form (ICF) and in this<br>       protocol<br><br>        - All sexes<br><br>        - 11 years of age or older at the start of the study and weight =30 kg at the<br>         screening of Part B<br><br>        - Participants who are CATT test or HAT RDT positive (information provided by the<br>         mobile team and included into TrypElim (see Part A)<br><br>        - Participants who are able to ingest oral tablets<br><br>        - Participants with known address and/or contact details provided<br><br>        - Participants who are able to comply with the schedule of follow-up visits and<br>         other requirements of the study<br><br>        - Participants must agree not take part in any other clinical trials during the<br>         participation in part B of this study<br><br>        - Participants of child-bearing potential must be willing to use appropriate<br>         contraceptive methods.<br><br>    Exclusion Criteria:<br><br>     - • Individuals with a positive parasitological exam on the spot at baseline (mAECT or<br>       lymph gland puncture)<br><br>        - Participants previously treated for g-HAT or previously treated because of gHAT<br>         seropositive results<br><br>        - Pregnant women<br><br>        - Breast-feeding women<br><br>        - Children =11 years, but under 30kg body weight at the screening for part B<br><br>        - Clinically significant medical condition that could, in the opinion of the<br>         investigator, jeopardise the subject's safety or participation in the study<br><br>        - Individuals presenting a jaundice at screening<br><br>        - Participants who are taking, or who are expected to need to start within 3<br>         months, a medicine (including traditional or herbal) which may interact with<br>         acoziborole and which cannot be stopped or adjusted (please refer to investigator<br>         manual or contact DNDi)<br>   ",,"Human African Trypanosomiasis","Drug: Treatment of seropositive individuals (positive serology test, but parasitology not confirmed)","Interruption of transmission of T.b. gambiense;Assessment of safety","Economic evaluation;assessment of the performance of several diagnostic tests",STROgHAT,"Please refer to primary and secondary sponsors","Institute of Tropical Medicine, Belgium;Institut de Recherche pour le Developpement;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;Ministry of Public Health, Democratic Republic of the Congo",,,,,,,,,,,,,,,,,,,Yes,False,"          "
ISRCTN15318880,"19 February 2024","Hidden transmission routes and attitudes towards sleeping sickness in Nigeria","Contribution of maternal transmission and silent carriers in the epidemiology and persistence of African trypanosomiasis in human populations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ",,"Accord (United Kingdom)",07/02/2024,"  20240207","10/13/2025 15:57:23",ISRCTN,https://www.isrctn.com/ISRCTN15318880,Recruiting,No,,,Both,01/11/2023,400,Observational,"Cross-sectional cohort study  (Screening)","Not Applicable","Nigeria;United Kingdom",Ayodele,Majekodunmi,"1 George Square",ayo.majekodunmi@ed.ac.uk,"+44 (0)131 650 8301",,"Inclusion criteria: 1. Willing and able to provide written informed consent<br>2. Individuals aged 18 years and above and residing in the study area for the questionnaire aspect of the study<br>3. Individuals over the age of 1 years old and residing in the study area for the blood sampling aspect of the study<br>4. Previously tested positive or are related to primary case from prior study<br>5. Key Informants which will include Ministerial officials, local government policymakers, non-governmental organizations, WHO or FAO representatives in Nigeria, and key academic research contacts<br>","Exclusion criteria: 1. Unwillingness or unable to provide consent<br>2. Failure to establish relatedness primary case<br>3. Individuals aged less than 18 years for the questionnaire aspect of the study<br>4. Individuals less than 1 years old for the blood sampling aspect of the study<br>","Attitudes and knowledge of Human African Trypanosomiasis (HAT), and the contribution of silent carriers and maternal transmission of HAT in Nigeria <br>Infections and Infestations","People who have previously had Human African Trypanosomiasis (HAT) will be recruited alongside their family members in their local towns and tested using in-field diagnostics for HAT, as well as blood stored on filter paper to be tested by PCR. They will then answer questions to elucidate attitudes and knowledge of HAT. Additionally, policymakers will be interviewed regarding the impact of COVID-19 on the neglected tropical diseases (NTDs) work in Nigeria.<br><br>Intervention 1<br>Testing of community members for HAT to establish occurrences of HAT and their distribution in the community<br> <br>Materials include card agglutination tests for trypanosomiasis (CATT), filter paper, finger prick needles, PPE, alcohol swabs and plasters. The procedure will be to take finger prick blood samples from individuals who had a previously positive CATT/PCR test in 2020 and their family members. These samples will be tested in the field with CATT tests as well as stored on filter paper for later PCR testing in the laboratory. Local community healthcare workers and government-trained phlebotomists with phlebotomy and HAT diagnostic training and experience will collect blood samples and perform in-field testing assisted by study investigators. Laboratory testing will be performed by study investigators who have been trained in sample extraction, processing and PCR. The finger pricking and in-field testing will happen individually, face-to-face in community health settings and town halls. The PCR testing will be undertaken in a University of Edinburgh laboratory. Each person will have a single finger prick/testing appointment no repeats will be taken. The laboratory testing will be repeated as necessary to meet the demands of research rigour. This will be taken from the stored samples and so will not ","Individuals test positive or negative for HAT measured using the standard protocols for Card Agglutination Trypanosomiasis Test (CATT) within 24 hours of sample collection or by PCR within 1 year of sample collection","1. Number of asymptomatic carriers assessed by the number of positive individuals with no symptoms measured using CATT within 24 hours of sample collection or PCR within 1 year of sample collection<br>2. Maternal transmission cannot be assured but suspected if multiple family members test positive measured using CATT within 24 hours of sample collection or PCR within 1 year of sample collection<br>3. Attitudes and knowledge of HAT measured using a questionnaire and focus group on the same day as sample collection<br>4. Knowledge of the impact of COVID-19 on neglected tropical diseases in Nigeria ascertained by interview of policymakers at baseline<br><br>","Nil known;Nil known;AC23088, NHREC/01/01/2007-15/07/2019","University of Edinburgh, Zhejiang University",,Approved,25/04/2023,"National Health Research Ethics Committee of Nigeria (NHREC) ; ref: NHREC/01/01/2007- 25/04/2023C","Department of Health Planning, Research & Statistics, Federal Ministry of Health, 11th Floor, Federal Secretariat Complex Phase III, Ahmadu Bello Way, Abuja, -, Nigeria","+234 09 523 8367",deskofficer@nhrec.net,Yes,,,,31/03/2024,,,,,,"Data sharing statement to be made available at a later date","Planned to publication in a high-impact peer reviewed journal",No,False,"          "
NCT06060600,"9 October 2023","A Retrospective Analysis of Suramin Treatment for Stage 1 TBR","A Retrospective Analysis of Suramin Treatment for Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (S1 TBR HAT) in Uganda and Malawi",,Paxmedica,12/09/2023,"  20230912","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT06060600,"Not recruiting",No,N/A,N/A,All,02/01/2023,345,Observational,,,"United States"," ","jennifer L bonfrisco",,,,Paxmedica,"<br>    Inclusion Criteria:<br><br>     - Suramin-treated cohort:<br><br>        - Patient records must meet all the following criteria to be included in the<br>         suramin-treated cohort:<br><br>        - Male or female of any age; age or sex must be included.<br><br>        - Treatment with at least four full doses of suramin (not including the test dose).<br><br>        - Onset date or duration of symptoms associated with S1 TBR HAT is available.<br><br>        - An outcome is required; any mention of a clinical outcome is acceptable.<br><br>        - Must live in an area endemic for TBR HAT<br><br>        - Documented HAT diagnosis<br><br>        - Positive parasitology for HAT (observed in blood sample or a standard test).<br><br>    Natural History cohort:<br><br>     - Treatment records from a cohort of approximately 200 patients who were hospitalized<br>       between 1901 and 1910 during the 1900-1920 HAT epidemic<br><br>     - Treatment records must have sufficient information for analysis including:<br><br>        - Demographic data: age or sex must be included<br><br>        - Diagnosis: HAT diagnosis is confirmed by blood or lymph gland fluid analysis and<br>         parasites observed or HAT symptoms during the epidemic. For example, if the<br>         records state that a lymph node biopsy was performed, any result of the biopsy<br>         (e.g., documentation that trypanosomes were observed), a documentation of the HAT<br>         diagnosis, or mention of HAT symptoms such as sleepiness or excess sleeping are<br>         all acceptable. Symptoms alone are not sufficient, but a notation of biopsy and<br>         mention of HAT symptoms is acceptable.<br><br>        - Outcome: An outcome is required; any mention of a clinical outcome is acceptable.<br><br>    Exclusion Criteria:<br><br>    Patient records that meet any of the following criteria will be excluded from the<br>    suramin-treated cohort:<br><br>     - Reported duration of symptoms for more than 2 months at time of presentation at a<br>       healthcare facility.<br><br>     - Stage 2 TBR HAT as determined by examination of cerebrospinal fluid (CSF) using WHO<br>       criteria, which classify patients with the presence of trypanosomes in the CSF and/or<br>       a WBC count >5 cells/mm3 as Stage 2 TBR HAT at time of presentation to a healthcare<br>       facility.<br><br>     - Evidence of Stage 2 TBR HAT symptoms at time of presentation to a healthcare facility.<br><br>     - Required medication treatment for Stage 2 illness (melarsoprol) prior to time of<br>       presentation to a healthcare facility.<br><br>     - Known to have had Trypanosoma Brucei Gambiense (TBG) HAT or became ill while<br>       travelling from an area known to be endemic for TBG HAT<br><br>     - Duration of HAT symptoms for more than 6 months. Survival for more than 6 months with<br>       TBR HAT is unlikely.<br>   ",,"Trypanosoma Brucei Rhodesiense; Infection",,"The primary efficacy endpoint is survival of patients treated with suramin compared to the natural history cohort.","The secondary objective is to describe the safety and tolerability of suramin.",PAX-HAT-301,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT05637632,"9 October 2023","Assessment of Recombinant HAT-RDT Specificity","Assesslebt of Recombinant HAT-RDT Specificity",,"Institute of Tropical Medicine, Belgium",24/11/2022,"  20221124","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT05637632,"Not recruiting",No,"12 Years",N/A,All,20/09/2022,1504,Observational,,,"Congo, The Democratic Republic of the"," ","Epco Hasker, Phd PH",,,,"Insitute of Tropical Medicine","<br>    Inclusion Criteria:<br><br>     - Willing and able to provide written informed consent (and assent for minors 12-17years<br>       old)<br><br>     - Be enrolled in routine HAT screening activities dony by the mobile unit (PNLTHA mobile<br>       unit routine active screening teams that visit villages at risk for HAT). People<br>       living in the village are targeted for screening.<br><br>     - Participants must be at least 12 years old<br><br>    Exclusion Criteria:<br><br>     - Chilrden younger than 12 years old<br><br>     - previously treated for HAT<br><br>     - refusal to provide informed consent<br>   ",,"Human African Trypanosomiasis",,"Specificity of recombinant CORIS rapid diagnostic test for HAT;Specificity of recombinant BIOLINE rapid diagnostic test for HAT",iELISA;Molecular,HAT-RDT,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT05466630,"15 April 2024","Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis","Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis in Côte d'Ivoire and Guinea",SpeSerTryp,"Institut de Recherche pour le Developpement",07/07/2022,"  20220707","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT05466630,"Not recruiting",No,"10 Years",N/A,All,20/06/2022,1095,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). ",N/A,"Côte D'Ivoire;Guinea;Côte D'Ivoire;Guinea"," ; ","Martial N'Djetchi Kassi;Oumou Camara",,;,;,"Université Jean Lorougnon Guédé de Daloa;Programme National de lutte contre de la THA en Guinée","<br>    Inclusion Criteria:<br><br>     - at least 10 years old<br><br>     - signed the informed consent form (in case of minor: parent or tutor signs informed<br>       consent form and minor signs ascent form)<br><br>    Exclusion Criteria:<br><br>     - severe anemia hindering blood sampling<br><br>     - severe illness hindering obtention of informed consent (eg coma, cognitive deficiency<br>       etc)<br><br>     - history of sleeping sickness<br>   ",,"Human African Trypanosomiasis;Sleeping Sickness;Trypanosoma Brucei Gambiense; Infection;West African Sleeping Sickness","Diagnostic Test: Serological field test for HAT;Diagnostic Test: malaria rapid test;Diagnostic Test: Immunologic laboratory tests;Diagnostic Test: Molecular laboratory tests","Specificity of serological field test for diagnosis of HAT during active screening in Côte d'Ivoire and Guinea","Specificity of serological field test for diagnosis of HAT during active screening in Côte d'Ivoire and Guinea, in function of malaria status;Specificity of immunologic and molecular laboratory tests for diagnosis of HAT in serological suspects",SpeSerTryp,"Please refer to primary and secondary sponsors","Foundation for Innovative New Diagnostics;Programme National de lutte contre la THA, Guinée;Université Jean Lorougnon Guédé, Daloa;Institut Pasteur, Guinée;Institut Pierre Richet, Guinée",,,,,,,,,,,,,,,,,,,No,False,"          "
NCT04099628,"25 April 2022","Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring","Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring",DiTECT-HAT-WP3,"Institut de Recherche pour le Developpement",19/09/2019,"  20190919","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT04099628,"Not recruiting",No,"4 Years",N/A,All,01/09/2019,13747,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). ",N/A,"Burkina Faso;Congo, The Democratic Republic of the;Côte D'Ivoire;Burkina Faso;Congo, The Democratic Republic of the;Côte D'Ivoire"," ","Veerle Lejon, PhD, HDR",,,,"Institut de Rechercher pour le Développement","<br>    Inclusion Criteria:<br><br>     - Permanent resident of village (in low to zero prevalence HAT focus) for minimum 1 year<br><br>    Exclusion Criteria:<br><br>     - Previously treated for HAT (irrespective of time elapsed since treatment)<br><br>     - No informed consent<br><br>     - < 4 years old<br>   ",,"Human African Trypanosomiasis;Sleeping Sickness;Trypanosoma Brucei Gambiense; Infection;West African Sleeping Sickness;African Trypanosomiases;Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, Gambiense","Diagnostic Test: Rapid diagnostic test (RDT); Serological and molecular tests on DBS","Sensitivity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on the population at risk;Specificity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on the population at risk",,DiTECT-HAT-WP3,"Please refer to primary and secondary sponsors","Ministry of Public Health, Democratic Republic of the Congo;Institut National de Sante Publique;CIRDES;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;Institute of Tropical Medicine, Belgium;University of Liverpool",,,,,,,,,,,,,,,,,,,No,False,"          "
NCT03974178,"31 October 2022","Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense","Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense: a Multicentre, Open-label Clinical Trial",,"Drugs for Neglected Diseases",23/05/2019,"  20190523","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03974178,"Not recruiting",Yes,"6 Years",N/A,All,29/09/2019,45,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2/Phase 3",Malawi;Uganda;Malawi;Uganda," ","Enock Matovu, Prof",,,,"Makerere University","<br>    Inclusion Criteria:<br><br>     - Signed Informed Consent Form (plus assent for children)<br><br>     - = 6 years old<br><br>     - = 20 kg body weight<br><br>     - Ability to ingest at least one complete meal per day (or at least one Plumpy'Nut®<br>       sachet)<br><br>     - Karnofsky index = 40<br><br>     - Parasitological confirmed of T.b. rhodesiense infection<br><br>     - Having a permanent address or being traceable by others and willing and able to comply<br>       with follow-up visit schedule<br><br>     - Agreement to be hospitalised for a minimum of 13 days and to receive the study<br>       treatment<br><br>    Exclusion Criteria:<br><br>     - Active clinically relevant medical conditions other than HAT that may jeopardize<br>       subject safety or at the investigator discretion may interfere with participation in<br>       the study.<br><br>     - Compromised general health or severely deteriorated general condition, such as severe<br>       malnutrition, cardiovascular shock, respiratory distress, or terminal illness<br><br>     - Known hypersensitivity to fexinidazole, to any nitroimidazole drugs (e.g.<br>       metronidazole, tinidazole) or to any of the excipients<br><br>     - Patients previously enrolled in the study or having already received fexinidazole<br><br>     - Patients with severe hepatic impairment (ex: clinical signs of cirrhosis or jaundice)<br>   ",,"Trypanosoma Brucei Rhodesiense; Infection","Drug: Fexinidazole","Possibly Related fatality rate at the end of hospitalisation in stage 2 r-HAT patients","Success rate at the End of Treatment in all stages patients;Success and failure outcomes at the test of cure;Occurrence of adverse events and serious adverse events;Unsatisfactory clinical and parasitological response",DNDi-FEX-07-HAT,"Please refer to primary and secondary sponsors","European and Developing Countries Clinical Trials Partnership (EDCTP)",,,,,,,,,,,,,,,,,,,Yes,"True ","parent    "
NCT03394976,"15 January 2024","Prospective Evaluation of an RDT to Screen for Gambiense HAT and Diagnose P. Falciparum Malaria","Prospective Evaluation of a Rapid Diagnostic Test to Screen for Gambiense Human African Trypanosomiasis and Diagnose Plasmodium Falciparum Malaria",,"Foundation for Innovative New Diagnostics, Switzerland",11/12/2017,"  20171211","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT03394976,"Not recruiting",No,"6 Years",N/A,All,31/01/2022,0,Observational,,,,,,,,,,"<br>    Inclusion Criteria:<br><br>     - Age greater than or equal to 6 years<br><br>     - Provision of signed informed consent. For children (under the age of 18) provision of<br>       signed informed consent by a parent or legal guardian and an age appropriate assent.<br><br>    Exclusion Criteria:<br><br>     - Severe anaemia preventing collection of a sample of venous blood<br><br>     - Severe medical condition preventing informed consent and trial participation (e.g.<br>       coma, cognitive impairment, etc.)<br><br>     - For HAT true negatives only: history of previous HAT infection<br>   ",,"Human African Trypanosomiasis","Diagnostic Test: No intervention","specificity of the HAT/malaria combo test for gambiense HAT in passive screening;specificity of the SD BIOLINE HAT 2.0 test for gambiense HAT in passive screening;sensitivity of the HAT/malaria combo test for P. falciparum malaria in passive screening;sensitivity of the SD BIOLINE Malaria Ag P.f test for P. falciparum malaria in passive screening;specificity of the HAT/malaria combo test for P. falciparum malaria in passive screening;specificity of the SD BIOLINE Malaria Ag P.f test for P. falciparum malaria in passive screening","specificity of the HAT/malaria combo test for gambiense HAT in passive screening in a population living in a setting where HAT is endemic;specificity of the SD BIOLINE HAT 2.0 test for gambiense HAT in passive screening in a population living in a setting where HAT is endemic;specificity of the HAT/malaria combo test for gambiense HAT in passive screening in a population living in a setting where HAT and animal trypanosomiasis are not endemic;specificity of the SD BIOLINE HAT 2.0 test for gambiense HAT in passive screening in a population living in a setting where HAT and animal trypanosomiasis are not endemic","HAT-malaria RDT evaluation","Please refer to primary and secondary sponsors","Makerere University;Ministry of Public Health, Democratic Republic of the Congo",,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT03356665,"1 March 2021","Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection","Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection",DiTECT-WP2,"Institut de Recherche pour le Developpement",24/11/2017,"  20171124","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03356665,"Not recruiting",No,"4 Years",N/A,All,01/08/2017,10700,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). ",N/A,"Congo, The Democratic Republic of the;Côte D'Ivoire;Guinea;Congo, The Democratic Republic of the;Côte D'Ivoire;Guinea"," ","Veerle Lejon, PhD",,,,"Institut de Recherche pour le Developpement","<br>    Inclusion Criteria:<br><br>     - Visit of or residence in a HAT endemic area<br><br>     - Clinical suspicion of HAT based on: Recurrent fever not responding to anti-malarial<br>       medication; or Headache for a long duration (>14 days); or presence of swollen lymph<br>       nodes in the neck; or Important weight loss; or Weakness; or Important scratching; or<br>       Amenorrhea, abortion(s), or sterility; or Coma; or Psychiatric problems<br>       (aggressiveness, apathy, mental confusion, increasing unusual hilarity, ...); or Sleep<br>       disruption (nocturnal insomnia and excessive diurnal sleeping); or Motor abnormalities<br>       (convulsions, abnormal movements, shaking, walking difficulties); or Speech disorders.<br><br>    Exclusion Criteria:<br><br>     - Previously treated for HAT (irrespective of time elapsed since treatment)<br><br>     - No informed consent<br><br>     - < 4 years old<br>   ",,"African Trypanosomiases;West African; Trypanosomiasis;Sleeping Sickness; West African;Trypanosoma Brucei Gambiense; Infection","Diagnostic Test: Rapid diagnostic test (RDT);Diagnostic Test: Serological and molecular tests on DBS","Sensitivity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on HAT clinical suspects;Specificity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on HAT clinical suspects",,DiTECT-HAT-WP2,"Please refer to primary and secondary sponsors","Ministry of Public Health, Democratic Republic of the Congo;Ministry of Health, Guinea;Institut National de Sante Publique;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;CIRDES;Institute of Tropical Medicine, Belgium;University of Liverpool",,,,,,,,,,,,,,,,,,,No,False,"          "
PACTR201704002215604,"24 June 2025","Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage","An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ",,DNDi,19/04/2017,"  20170419","10/13/2025 15:57:23",PACTR,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=2215,Recruiting,No,"6 Year(s)","100 Year(s)",Both,10/11/2016,174,Interventional,"Single group: all participants receive same intervention throughout study,Non-randomised","Not Applicable","Democratic Republic of the Congo;Democratic Republic of the Congo;Democratic Republic of the Congo;Democratic Republic of the Congo;Democratic Republic of the Congo;Democratic Republic of the Congo",Antoine,Tarral," Chemin Louis Dunant 15",atarral@dndi.org,+41229069260,"Head of HAT Clinical Program/DNDi","Inclusion criteria: * Male or female patient, including breastfeeding or pregnant women in the second or third trimester.<br>* ¿ 6 years of age.<br>* ¿ 20 kg body weight.<br>* Signed Informed Consent Form<br>* Trypanosomes detected in any body fluid.<br>* Physically able to ingest at least one solid meal per day.<br>* Able to take oral medication.<br>* Karnofsky Performance Status > 40%.<br>* Able to comply with the schedule of follow-up visits and with the study constraints.<br>* Easily reachable during the out-patient follow-up period.<br>* Willing to undergo lumbar punctures.<br><br>Eligibility Criteria for Out-patient Treatment:<br> - Accepting to be treated on an out-patient basis.<br> - Karnofsky Performance Status > 50%.<br> - Good understanding of the method of administration of fexinidazole by the patient and/or caregiver (checked using a questionnaire at the time of IMP dispensing).<br> - Residing close to the investigational centre, i.e. approximately one hour by road and/or boat, during the treatment period*.<br> - Easily reachable during the treatment period.<br> - No medical or psychiatric contraindications for treatment as out-patient.<br> - No pregnancy or breastfeeding.<br> - No neurological symptoms.<br>*The patient (and caregiver) is permitted to reside in a place different from his/her main place of residence during the treatment period.<br><br>","Exclusion criteria: * Active clinically relevant medical conditions other than HAT that, in the Investigator¿s opinion, could jeopardise patient safety or interfere with participation in the study, including but not limited to significant liver or cardiovascular diseases, HIV infection, CNS trauma or seizure disorders, coma or altered consciousness not related to HAT.<br>* Severe renal or hepatic impairment defined as:<br> o elevated creatinine at > 3 times the upper limit of normal (ULN)<br> o elevated ALT, AST or bilirubin at > 3 ULN<br>* Severely deteriorated general condition, such as cardiovascular shock, respiratory distress or terminal illness.<br>* Any condition (except symptoms of HAT) that compromises ability to communicate with the Investigator as required for completion of the study.<br>* Any contraindication to imidazole products (known hypersensitivity to imidazoles).<br>* Treatment for HAT within 2 years prior to inclusion.<br>* Prior enrolment in the study or prior intake of fexinidazole.<br>* Foreseeable difficulty in complying with the schedule of follow-up visits (migrants, refugees, itinerant traders, etc.).<br><br>Temporary Non-inclusion Criteria:<br>* Recovery period after antimalarial treatment and/or treatment of helminthiasis (at least 3 days).<br>* Uncontrolled diabetes or hypertension or any patients requiring clinical stabilisation; wait until appropriate treatment to control the disease has been initiated.<br>* First trimester of pregnancy.<br>* Traumatic lumbar puncture at Screening i.e. red blood cells visible in CSF; wait for 48 hours before repeating lumbar puncture.<br><br>"," <br>Human African Trypanosomiasis due to T.b. gambiense <br>Human African Trypanosomiasis due to T.b. gambiense;Human African Trypanosomiasis due to T.b. gambiense;Human African Trypanosomiasis due to T.b. gambiense",;Fexinidazole,"Success or failure for patients any stage HAT","Occurrence of grade ¿ 3 adverse events (AEs);Occurrence of any serious adverse event (SAE);PK measure: Presence of fexinidazole and/or its main metabolites in the blood for PK analyses;Outpatients compliance: Number of tablets left over and patient's responses to the questionnaire;Outpatients compliance: Patient's responses to the questionnaire;Feasibility of self-management of treatment intake in outpatients based on interview and left over tablets at D11;questionnaire on acceptability of packaging for outpatients only questionnaire to be completed by patients and caregivers;Whole blood concentration of fexinidazole and its metabolites from dry blood spot of inpatients",,DNDi,,Approved,13/09/2016,"Comité d'Ethique de l'université protestante au Congo"," Croisement des l'avenue de Libération et du Boulevard Triomphal, Kinshasa/",,,,,,,,,,,,,,,No,False,"          "
NCT03112655,"1 March 2021","Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: Early Test-of-cure","Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP4 Early Test-of-cure",DiTECT-WP4,"Institut de Recherche pour le Developpement",31/03/2017,"  20170331","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03112655,"Not recruiting",No,"15 Years",N/A,All,24/02/2017,88,Interventional,"Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). ",N/A,"Congo, The Democratic Republic of the"," ","Veerle Lejon, PhD",,,,"Institut de Recherche pour le Developpement","<br>    Inclusion Criteria:<br><br>     - Eligible for participation in DNDi-OXA-02-HAT clinical trial<br><br>    Exclusion Criteria:<br><br>     - Excluded for DNDi-OXA-02-HAT clinical trial; No informed consent for participation in<br>       the DiTECT-HAT-WP4 study<br>   ",,"African Trypanosomiasis;African; Trypanosomiasis, West;Sleeping Sickness; West African;Trypanosoma Brucei Gambiense; Infection","Diagnostic Test: RNA and neopterin detection","Sensitivity of SL-RNA detection in blood, SL-RNA detection in cerebrospinal fluid and of neopterin & 5-hydroxytryptophan quantification in cerebrospinal fluid for relapse after human African trypanosomiasis treatment;Specificity of SL-RNA detection in blood, SL-RNA detection in cerebrospinal fluid and of neopterin & 5-hydroxytryptophan quantification in cerebrospinal fluid for cure after human African trypanosomiasis treatment","Sensitivity and specificity SL-RNA detection in blood for outcome assesment after treatment for human African trypanosomiasis;Sensitivity and specificity SL-RNA detection in cerebrospinal fluid for outcome assesment after treatment for human African trypanosomiasis;Sensitivity and specificity by ROC analysis of neopterin & 5-hydroxytryptophan quantification in cerebrospinal fluid for outcome assesment after treatment for human African trypanosomiasis",DiTECT-HAT-WP4,"Please refer to primary and secondary sponsors","Institute of Tropical Medicine, Belgium;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;Ministry of Public Health, Democratic Republic of the Congo",,,,,,,,,,,,,,,,,,,No,False,"          "
NCT03087955,"31 January 2022","Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense","Efficacy and Safety Study of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study",OXA002,"Drugs for Neglected Diseases",07/03/2017,"  20170307","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03087955,"Not recruiting",No,"15 Years",N/A,All,11/10/2016,260,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2/Phase 3","Congo, The Democratic Republic of the;Guinea;Congo, The Democratic Republic of the;Guinea"," ","Victor Kande Betu Kumeso, Dr",,,,"Ministère de la Santé","<br>    Inclusion Criteria:<br><br>     - Male or female patient<br><br>     - 15 years of age or older<br><br>     - Signed informed consent form (as well as assent from illiterate and under-age<br>       patients, and those unable to give consent)<br><br>     - Karnofsky Performance Status above 50<br><br>     - Able to ingest oral tablets<br><br>     - Having a permanent address or being traceable by other persons<br><br>     - Able to comply with the schedule of follow-up visits and requirements of the study<br><br>     - Agreement to be hospitalised in order to receive treatment<br><br>     - For patients with late-stage HAT:<br><br>        - Confirmation of g-HAT by detection of the parasite in the blood and/or the lymph<br>         and/or the CSF, at the investigational centre<br><br>        - If trypanosomes are found in the blood or lymph, but not in the CSF, the CSF WBC,<br>         measured at the investigational centre, must be above 20/µL for the patient to be<br>         included in the cohort of patients with late-stage HAT<br><br>     - For patients with early- or intermediate-stage HAT:<br><br>        - Confirmation of g-HAT by detection of the parasite in the blood and/or the lymph,<br>         at the investigational centre<br><br>        - Absence of parasites in the CSF<br><br>        - The CSF WBC, measured at the investigational centre, must be between 6 and 20/µL<br>         for the patient to be included in the cohort of patients with intermediate-stage<br>         HAT and equal to or below 5/µL for the patient to be included in the cohort of<br>         patients with early-stage HAT.<br><br>    Exclusion Criteria:<br><br>     - Severe malnourishment, defined as body-mass index (BMI) below 16<br><br>     - Pregnancy or breastfeeding (for women of child-bearing potential, confirmed pregnancy<br>       on a urine pregnancy test performed within 24 hours prior to administration of<br>       SCYX-7158)<br><br>     - Clinically significant medical condition that could, in the opinion of the<br>       Investigator, jeopardise the patient's safety or interfere with participation in the<br>       study, including, but not limited to significant liver or cardiovascular disease,<br>       suspected or proven active infection, central nervous system trauma or seizure<br>       disorder, coma or consciousness disturbances<br><br>     - Severely deteriorated health status, e.g. due to cardiovascular shock, respiratory<br>       distress syndrome or end-stage disease<br><br>     - Previously treated for HAT (except prior treatment with pentamidine)<br><br>     - Prior enrolment in the study<br><br>     - Foreseeable difficulty complying with follow-up, including migrant worker, refugee<br>       status, itinerant trader etc.<br><br>     - Current alcohol abuse or drug addiction<br><br>     - Not tested for malaria and/or not having received appropriate treatment for malaria<br><br>     - Not having received appropriate treatment for soil-transmitted helminthiasis<br><br>     - Clinically significant abnormal laboratory values including Aspartate<br>       AminoTransferase(AST) and/or AlanineAminoTransferase (ALT) more than 2 times the upper<br>       limit of normal (ULN), total bilirubin more than 1.5 ULN, severe leukopenia at less<br>       than 2000/mm3, Potassium below 3.5 mmol/L, any other clinically significant abnormal<br>       laboratory value<br>   ",,"Trypanosomiasis, African;Gambiense Trypanosomiasis;Sleeping Sickness","Drug: Acoziborole (SCYX-7158)","Success or failure for patients in late stage HAT","Success or failure for all stage HAT patients;Time to Failure in Patients with Late-stage HAT;Occurence of adverse events;Occurence of serious advers events;Pharmacokinetics measure;Pharmacokinetics measure;Electrocardiogram measure;Electrocardiogram measure;Electrocardiogram measure;Electrocardiogram measure;Electrocardiogram measure",DNDi-OXA-02-HAT,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT03025789,"18 July 2023","Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage","An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage",,"Drugs for Neglected Diseases",11/11/2016,"  20161111","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT03025789,"Not recruiting",No,"6 Years",N/A,All,10/11/2016,174,Interventional,"Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3","Congo, The Democratic Republic of the;Guinea;Congo, The Democratic Republic of the;Guinea"," ","Victor Kande Betu Kumeso, MD",,,,"Ministry of Health, Kinshasa, The Democratic Republic of the Congo","<br>    Inclusion Criteria:<br><br>     - Male or female patient, including breastfeeding or pregnant women in the second or<br>       third trimester.<br><br>     - = 6 years of age.<br><br>     - = 20 kg body weight.<br><br>     - Signed Informed Consent Form and Assent Form for patients less than 18 years of age<br><br>     - Trypanosomes detected in any body fluid.<br><br>     - Physically able to ingest at least one solid meal per day.<br><br>     - Able to take oral medication.<br><br>     - Karnofsky Performance Status > 40%.<br><br>     - Able to comply with the schedule of follow-up visits and with the study constraints.<br><br>     - Easily reachable during the out-patient follow-up period.<br><br>     - Willing to undergo lumbar punctures.<br><br>    Exclusion Criteria:<br><br>     - Active clinically relevant medical conditions other than HAT that, in the<br>       Investigator's opinion, could jeopardise patient safety or interfere with<br>       participation in the study, including but not limited to significant liver or<br>       cardiovascular diseases, HIV infection, CNS trauma or seizure disorders, coma or<br>       altered consciousness not related to HAT.<br><br>     - Severe renal or hepatic impairment defined as:<br><br>    elevated creatinine at > 3 times the upper limit of normal (ULN) elevated ALT, AST or<br>    bilirubin at > 3 ULN<br><br>     - Severely deteriorated general condition, such as cardiovascular shock, respiratory<br>       distress or terminal illness.<br><br>     - Any condition (except symptoms of HAT) that compromises ability to communicate with<br>       the Investigator as required for completion of the study.<br><br>     - Any contraindication to imidazole products (known hypersensitivity to imidazoles).<br><br>     - Treatment for HAT within 2 years prior to inclusion.<br><br>     - Prior enrolment in the study or prior intake of fexinidazole.<br><br>     - Foreseeable difficulty in complying with the schedule of follow-up visits (migrants,<br>       refugees, itinerant traders, etc.).<br><br>    Temporary Non-inclusion Criteria:<br><br>     - Recovery period after antimalarial treatment and/or treatment of helminthiasis (at<br>       least 3 days).<br><br>     - Uncontrolled diabetes or hypertension or any patients requiring clinical<br>       stabilisation; wait until appropriate treatment to control the disease has been<br>       initiated.<br><br>     - First trimester of pregnancy.<br><br>     - Traumatic lumbar puncture at Screening i.e. red blood cells visible in CSF; wait for<br>       48 hours before repeating lumbar puncture.<br><br>    Eligibility Criteria for Out-patient Treatment<br><br>     - Accepting to be treated on an out-patient basis;<br><br>     - Karnofsky Performance Status > 50%;<br><br>     - Good understanding of the method of administration of fexinidazole by the patient<br>       and/or caregiver* (checked using a questionnaire at the time of dispensing<br>       fexinidazole);<br><br>     - Residing close to the investigational centre, i.e. approximately one hour by road<br>       and/or boat, during the treatment period**;<br><br>     - Easily reachable during the treatment period;<br><br>     - No medical or psychiatric contraindications for treatment as out-patient;<br><br>     - No pregnancy or breastfeeding;<br><br>     - No neurological symptoms.<br>   ",,"Trypanosomiasis, African;Sleeping Sickness;Trypanosomiasis; Gambian","Drug: Fexinidazole","Percentage of participants whose treatment outcome at Month 18 is a success","Percentage of participants whose treatment outcome at Month 12 is a success;Occurrence of grade = 3 adverse events (AEs) including laboratory and haematological abnormalities (if considered clinically significant);Occurrence of any serious adverse event (SAE);Occurrence of temporary or permanent treatment discontinuation (inpatient or outpatient) for reasons related to safety;Occurrence of hospitalization (outpatient only) for reasons related to safety;Occurrence of permanent treatment discontinuation (inpatient or outpatient) for reasons related to safety;Pharmacokinetic measure to assess patient compliance;Outpatients compliance to the full course of the 10-day treatment;Outpatients compliance to the 10-day treatment posology, including taking the correct number of tablets during the 2 phases of treatment and taking tablets all at once every day, with food and without any interruption of treatment;Feasibility of self-management of treatment intake in outpatients: occurrence of temporary treatment discontinuation;Feasibility of self-management of treatment intake in outpatients: occurrence of permanent treatment discontinuation;Feasibility of self-management of treatment intake in outpatients: delayed treatment start;Feasibility of self-management of treatment intake in outpatients: hospitalization during the treatment period due to non-compliance;Acceptability of packaging in outpatients: full understanding of instructions concerning dosing regimen;Acceptability of packaging in outpatients: help requested to follow the treatment;Acceptability of packaging in outpatients: instructions found helpful;Whole blood concentration of fexinidazole from dry blood spot, measured 24 hours after the last dose of fexinidazole;Whole blood concentration of fexinidazole metabolite M1 from dry blood spot, measured 24 hours after the last dose of fexinidazole;Whole blood concentration of fexinidazole metabolite M2 from dry blood spot, measured 24 hours after the last dose of fexinidazole",DNDi-FEX-09-HAT,"Please refer to primary and secondary sponsors",Sanofi,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT02184689,"12 December 2020","Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study","Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study",,"Drugs for Neglected Diseases",19/06/2014,"  20140619","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02184689,"Not recruiting",No,"6 Years","14 Years",All,03/05/2014,125,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2/Phase 3","Congo, The Democratic Republic of the",,,,,,,"<br>    Inclusion Criteria:<br><br>     - Informed consent form signed by one of the parents or the child's legal representative<br><br>     - Child assent to participate in the study collected in the presence of an impartial<br>       witness<br><br>     - Age between 6 and 15 years old<br><br>     - > 20 Kg bodyweight<br><br>     - Boy or girl<br><br>     - Able to ingest at least one complete meal per day (or at least one Plumpy'Nut® sachet)<br><br>     - Able to swallow 600mg fexinidazole tablets<br><br>     - Karnofsky index > 50<br><br>     - Presence of trypanosomes in blood and/or lymph and/or CSF<br><br>     - Permanent address and ability to comply with follow-up visit schedule<br><br>    Exclusion Criteria:<br><br>     - Child refusing to be included in the trial<br><br>     - Bodyweight < 20 Kg<br><br>     - Severe malnutrition, defined as having a BMI below 16 (- 2 Z-score of the norm<br>       according to WHO 2007 Growth reference data)<br><br>     - Inability to take oral medication<br><br>     - Pregnancy or breastfeeding<br><br>     - Clinically relevant medical condition other than HAT that, in the Investigator's<br>       opinion, may jeopardize subject safety or interfere with participation in the study,<br>       including but not limited to significant liver or cardiovascular disease, active<br>       documented or suspected infection, central nervous system (CNS) trauma or seizure<br>       disorders, coma or altered consciousness<br><br>     - Severely deteriorated general condition, such as cardiovascular shock, respiratory<br>       distress, or terminal illness<br><br>     - Any medical condition (except HAT-specific symptoms) hindering communication with the<br>       Investigator as required for the completion of this study<br><br>     - Any contraindication to imidazole products (known hypersensitivity to imidazoles)<br><br>     - History of HAT treatment in the past 2 years<br><br>     - Patients previously enrolled in the study or having already received fexinidazole.<br><br>     - Expected follow-up difficulties (migrants, refugees, itinerant vendors, etc.).<br><br>     - Current alcohol or drug abuse<br><br>     - Clinically significant abnormal laboratory findings, including ASAT and/or ALAT > 2<br>       times ULN // Total bilirubin > 1.5 times ULN // Severe leukopenia (< 2000/mm3) //<br>       Potassium (K+) < 3.5 mmol // Any other clinically significant abnormal laboratory<br>       value (see details in Investigator Manual)<br><br>     - Pregnancy confirmed by a positive urine pregnancy test obtained within 24 hours (h)<br>       prior to start of study treatment (see Section 5.8.3 Contraception; p36) for girls<br>       over 12 years old and over<br><br>     - ECG abnormalities assessed by a central cardiologist<br><br>     - QTcF= 450 ms, as measured automatically (if first measurement is abnormal, a second<br>       assessment will be done at least 10-20 min later, with the patient in resting<br>       position).<br><br>     - Patients not tested for malaria and/or not treated adequately for this infection<br><br>     - Patients not treated adequately for soil transmitted helminthic diseases<br>   ",,"Human African Trypanosomiasis (HAT)","Drug: fexinidazole","Outcome (success or failure) at the test of cure (ToC)",,DNDiHATFEX006,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT02169557,"12 December 2020","Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study","Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study",,"Drugs for Neglected Diseases",15/05/2014,"  20140515","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02169557,"Not recruiting",No,"15 Years",N/A,All,30/04/2014,230,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2/Phase 3","Congo, The Democratic Republic of the",,,,,,,"<br>    Inclusion Criteria:<br><br>     - Signed informed consent<br><br>     - 15 years old or more<br><br>     - Male or female<br><br>     - Ability to ingest at least one complete meal per day (or at least one Plumpy'Nut®<br>       sachet)<br><br>     - Karnofsky index > 50<br><br>     - Presence of trypanosomes in blood or lymph<br><br>     - Absence of trypanosomes in CSF<br><br>     - Permanent address and ability to comply with the follow-up visit schedule<br><br>     - Patient agreeing to be hospitalized to receive the treatment<br><br>    Exclusion Criteria:<br><br>     - Severely malnutrition, defined as BMI < 16.<br><br>     - Inability to take oral medication.<br><br>     - Pregnancy or breastfeeding (a urine pregnancy test will be performed in all women of<br>       childbearing age within 24 h prior to treatment).<br><br>     - Clinically relevant medical condition other than HAT that, in the Investigator's<br>       opinion, may jeopardize patient safety or interfere with participation in the study,<br>       including but not limited to significant liver or cardiovascular disease, documented<br>       or suspected active infection (including AIDS), CNS trauma or seizure disorders, coma<br>       or altered consciousness.<br><br>     - Severely deteriorated general condition, e.g. cardiovascular shock, respiratory<br>       distress syndrome, or terminal illness.<br><br>     - Any medical condition (except HAT specific symptoms) hindering communication with the<br>       Investigator as required for the completion of this study.<br><br>     - Any contraindication to imidazole products (known hypersensitivity to imidazoles).<br><br>     - History of HAT treatment in the past 2 years.<br><br>     - Patients previously enrolled in the study or having already received fexinidazole.<br><br>     - Expected follow-up difficulties (migrants, refugees, itinerant vendors, etc.).<br><br>     - Current alcohol or drug abuse.<br><br>     - Clinically significant abnormal laboratory value, such as:<br><br>     - Alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) > 2 times ULN<br><br>     - Total bilirubin (TBIL) > 1.5 times ULN<br><br>     - Severe leukopenia (< 2000/mm3)<br><br>     - Potassium (K+) < 3.5 mmol/L<br><br>     - Any clinically significant abnormal value (see details in Investigator Manual)<br><br>     - Pregnancy confirmed by a positive urine pregnancy test obtained within 24 h prior to<br>       start of study treatment (see Section 5.8.3 Contraception; p35) QTcF = 450 ms as<br>       measured automatically (if the first measurement is abnormal, a second assessment will<br>       be done at least 10-20 min later, with the patient in resting position)<br><br>     - Patients not tested for malaria and/or not treated adequately for this infection<br><br>     - Patients not treated adequately for soil-transmitted helminthic diseases<br>   ",,"Human African Trypanosomiasis (HAT)","Drug: Fexinidazole","Outcome (success or failure) at the test of cure (ToC) visit 12 months after the end of treatment (EOT).","Success or failure at each visit between the End of treatment and 18 months visit.",DNDiHATFEX005,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT01766830,"7 November 2016","Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)","Evaluation of Rapid Diagnostic Tests (RDT) in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases (NTD) in Patients Presenting With Persistent Fever (=1 Week) in Cambodia, Nepal, Democratic Republic of the Congo and Sudan",,"University Hospital, Geneva",09/01/2013,"  20130109","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01766830,"Not recruiting",No,"5 Years",N/A,Both,01/01/2013,1927,Interventional,"Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic",N/A,"Cambodia;Congo, The Democratic Republic of the;Nepal;Sudan;Cambodia;Congo, The Democratic Republic of the;Nepal;Sudan"," ","François Chappuis, MD, PhD",,,,"University Hospitals, Geneva","<br>    Inclusion Criteria:<br><br>     - fever for = 1 week<br><br>     - = 5 years old (18 years onward in Cambodia)<br><br>    Exclusion Criteria:<br><br>     - unwilling or unable to give written informed consent<br><br>     - unable in the study physician's opinion to comply with the study requirements<br><br>     - existing laboratory confirmed diagnosis<br><br>     - need of immediate intensive care due to shock or respiratory distress<br>   ",,"Visceral Leishmaniasis;Human African Trypanosomiasis;Enteric Fever;Melioidosis;Brucellosis;Leptospirosis;Relapsing Fever;Rickettsial Diseases;HIV;Tuberculosis;Malaria;Amoebic Liver Abscess","Device: rk28 ICT;Device: IT LEISH (rK39);Device: Immunochromatographic HAT test;Device: HAT Serostrip;Device: Card Agglutination Trypanosoma Test (CATT)-10;Device: Typhidot M;Device: S. typhi IgM/IgG;Device: Test-it Typhoid IgM;Device: Test-it Leptospirosis IgM;Device: Leptospira IgG/IgM","Prevalence of Visceral Leishmaniasis (VL), Human African Trypanosomiasis (HAT) and other Neglected Tropical Diseases (NTDs);Identification of clinical and laboratory diagnostic indicators;Identification of reliable Rapid Diagnostic Tests (RDTs);Predictive values of RDTs","Cost-effectiveness of the diagnostic tests",260260;WP2-01-FEV,"Please refer to primary and secondary sponsors","Institute of Tropical Medicine, Belgium;B.P. Koirala Institute of Health Sciences;Institut National de Recherche Biomédicale, Kinshasa, DRC;University of Khartoum;Sihanouk Hospital Center of HOPE",,,,,,,,,,,,,,,,,,,No,False,"          "
NCT01685827,"12 December 2020","Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2","Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study",,"Drugs for Neglected Diseases",12/09/2012,"  20120912","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01685827,"Not recruiting",No,"15 Years",N/A,All,01/10/2012,394,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). ","Phase 2/Phase 3","Central African Republic;Congo, The Democratic Republic of the;Congo;Central African Republic;Congo;Congo, The Democratic Republic of the"," ","Victor KANDE, MD",,,,"HAT National Control Program in DRC","<br>    Inclusion Criteria:<br><br>     - 15 years old or more<br><br>     - Male or female<br><br>     - Able to ingest at least one complete meal per day (or at least one Plumpy'Nut® sachet)<br><br>     - Karnofsky index>50 (see Appendix 2 - Karnofsky Scale; p81)<br><br>     - Parasitologically confirmed late-stage African trypanosomiasis infection with T. b.<br>       gambiense in the blood and/or lymph and/or CSF, attested by mobile team report (with<br>       detail of exams performed and values of WBC measured in CSF) or done at the study<br>       centre. If parasitologically negative in CSF, WBC >20/µl detected in the CSF to<br>       document stage 2 infection.<br><br>     - Having a permanent address and able to comply with follow-up visit schedule<br><br>     - Signed Informed Consent Form<br><br>    Exclusion Criteria:<br><br>     - Severely malnourished patients, defined as having a BMI < 16.<br><br>     - Patients unable to take oral medication.*<br><br>     - Pregnancy or lactation<br><br>     - Active clinically relevant medical conditions that, in the Investigator's opinion, may<br>       jeopardize subject safety or interfere with participation in the study, including but<br>       not limited to significant liver or cardiovascular disease, active documented or<br>       suspected infection, CNS trauma or seizure disorders, coma or altered consciousness.<br><br>     - Severely deteriorated general condition, such as cardiovascular shock, respiratory<br>       distress, or terminal illness.<br><br>     - Any condition which compromises ability to communicate with the Investigator as<br>       required for the completion of this study.<br><br>     - Any contraindication to imidazole products (known hypersensitivity to imidazoles) and<br>       NECT (known hypersensitivity to eflornithine).<br><br>     - Patients previously treated for HAT.<br><br>     - Patients previously enrolled in the study.<br><br>     - Follow-up expectable difficulties (migrants, refugees, traders, etc.).<br><br>     - History of alcohol abuse or any drug addiction.<br><br>     - Clinically significant abnormal laboratory value<br><br>     - Pregnancy<br><br>     - Unstable ECG abnormalities<br><br>     - QTcF= 450 msec in resting position (confirmed by 2 measurement).<br><br>     - Patients not tested for malaria and/or treated adequately for this infection<br><br>     - Patients not treated adequately for soil transmitted helminthic diseases<br>   ",,"Human African Trypanosomiasis (HAT);Sleeping Sickness","Drug: Fexinidazole;Drug: Nifurtimox;Drug: Eflornithine","success or failure at 18 months FU visit","Safety endpoint;Safety endpoint;Pharmacokinetics endpoint;QT evaluation",DNDiFEX004,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT01533961,"28 September 2015","Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158","Randomized, Double-blind, Placebo-controlled Sequential Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCYX-7158 After Single Oral Ascending Doses in Healthy Male Volunteers",,"Drugs for Neglected Diseases",13/02/2012,"  20120213","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01533961,"Not recruiting",No,"18 Years","45 Years",Male,01/02/2012,136,Interventional,"Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment","Phase 1",France," ","Antoine Tarral, MD",,,,"Drugs for Neglected Diseases initiative","<br>    Inclusion Criteria:<br><br>     - Male healthy volunteers 18 to 45 years of age,<br><br>     - All subjects to be of sub-Saharan African origins with both parents of Sub-Saharan<br>       African origins too,<br><br>     - Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m2)<br>       from 18 to 28 kg/m2 at screening,<br><br>     - Able to communicate well with the Investigator and research staff and to comply with<br>       the requirements of the entire study,<br><br>     - Provision of written informed consent to participate as shown by a signature on the<br>       volunteer consent form,<br><br>     - Light smokers (less than 5 cigarettes per day) or subjects who are non-smokers. No<br>       smoking (or use of smoking substitute e.g. nicotine patch) is permitted from<br>       screening throughout the study,<br><br>     - Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not<br>       clinically significant by the principal Investigator. These will be measured after<br>       resting for 5 min.<br><br>     - Registered with the French Social Security in agreement with the French law on<br>       biomedical experimentation.<br><br>    Exclusion Criteria:<br><br>     - Who on direct questioning and physical examination have evidence of any clinically<br>       significant acute or chronic disease, including known or suspected HIV, HBV or HCV<br>       infection,<br><br>     - Who previously received SCYX-7158,<br><br>     - Who presented acute or chronic or history of symptoms of Gastro intestinal<br>       disturbances (GI) or on physical examination have evidence of any clinical signs of<br>       acute or chronic GI abnormality ( i.e hemorrhoids, GI bleeding…)<br><br>     - With any clinically significant abnormality following review of pre-study laboratory<br>       tests (aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) must be<br>       within normal ranges), vital signs, full physical examination and ECG,<br><br>     - Who are within the exclusion period defined in the National Register for Healthy<br>       Volunteers of the French Ministry of Health,<br><br>     - Who forfeit their freedom by administrative or legal award or who were under<br>       guardianship,<br><br>     - Unwilling to give their informed consent,<br><br>     - Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or<br>       anti-HIV 1/2 or anti- HCV antibodies<br><br>     - Who have a history of allergy, intolerance or photosensitivity to any drug,<br><br>     - Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to<br>       any drug,<br><br>     - Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per<br>       week, one unit = 8 g or about 10 mL of pure alcohol),<br><br>     - Who drink more than 8 cups daily of beverage containing caffeine,<br><br>     - Who have a positive laboratory test for urine drug screening (opiates, cocaine,<br>       amphetamine, cannabis, benzodiazepines),<br><br>     - Who have undergone surgery or have donated blood within 12 weeks prior to the start<br>       of the study,<br><br>     - Who have taken any prescribed or over the counter drug (including antacid drug), with<br>       the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first<br>       dose administration,<br><br>     - Who have any clinical condition or prior therapy which, in the opinion of the<br>       Investigator, made the subject unsuitable for the study,<br><br>     - Who participated to any clinical trial with an investigational drug in the past 3<br>       months preceding study entry.<br>   ",,"Trypanosomiasis;Trypanosomiasis, African;Protozoan Infections;Parasitic Diseases","Drug: SCYX-7158;Drug: Placebo","Occurence of adverse events (AEs)","Pharmacokinetic (blood concentration of SCYX-7158 and metabolite);Pharmacokinetic (urine concentration of SCYX-7158 and metabolite)",2011-004639-30;DNDiOXA001,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT01483170,"16 December 2017","Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food","Double-blind, Placebo Controlled, Randomized Multiple Ascending Dose Study in Fed Conditions for Ten Days Dosing Regimen With a Loading Dose to Evaluate the Safety, the Tolerability and the Pharmacokinetics of Oral Fexinidazole in 36 Healthy Male Sub-Saharan Volunteers.",,"Drugs for Neglected Diseases",29/11/2011,"  20111129","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01483170,"Not recruiting",No,"18 Years","45 Years",Male,01/09/2011,30,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 1",France;France;France;France;France," ; ; ; ; ","Lionel Hovsepian, MD;Lionel Hovsepian, MD;Lionel Hovsepian, MD;Lionel Hovsepian, MD;Lionel Hovsepian, MD",,;;;;,;;;;,"SGS Aster;SGS Aster;SGS Aster;SGS Aster;SGS Aster","<br>    Inclusion Criteria:<br><br>     - Male healthy volunteers 18 to 45 years of age,<br><br>     - All subjects to be of sub-Saharan African origins with both parents of sub-Saharan<br>       African origins too,<br><br>     - Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m)2<br>       from 18 to 28 kg/m2 inclusive at screening,<br><br>     - Able to communicate well with the Investigator and research staff and to comply with<br>       the requirements of the entire study,<br><br>     - Provision of written informed consent to participate as shown by a signature on the<br>       volunteer consent form,<br><br>     - Light smokers (less than 10 cigarettes per day) or subjects who are non-smokers. No<br>       smoking (or use of smoking substitute e.g. nicotine patch) is permitted from screening<br>       throughout the study,<br><br>     - Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not<br>       clinically significant by the principal Investigator. These will be measured after<br>       resting for 5 min,<br><br>     - Registered with the French Social Security in agreement with the French law on<br>       biomedical experimentation.<br><br>    Exclusion Criteria:<br><br>     - Who on direct questioning and physical examination have evidence of any clinically<br>       significant acute or chronic disease, including known or suspected HIV, HBV or HCV<br>       infection,<br><br>     - With any clinically significant abnormality following review of pre-study laboratory<br>       tests(ASAT, ALAT and alkaline phosphatase (ALP) must be within normal ranges), vital<br>       signs, full physical examination and ECG,<br><br>     - Who are within the exclusion period defined in the National Register for Healthy<br>       Volunteers of the French Ministry of Health,<br><br>     - Who forfeit their freedom by administrative or legal award or who were under<br>       guardianship,<br><br>     - Unwilling to give their informed consent,<br><br>     - Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or<br>       anti-HIV 1/2 or anti-HCV antibodies<br><br>     - Who have a history of allergy, intolerance or photosensitivity to any drug,<br><br>     - Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to<br>       any drug,<br><br>     - Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per<br>       week, one unit = 8 g or about 10 mL of pure alcohol),<br><br>     - Who drink more than 8 cups daily of beverage containing caffeine,<br><br>     - Who have a positive laboratory test for urine drug screening (opiates,<br>       cocaine,amphetamine, cannabis, benzodiazepines),<br><br>     - Who have undergone surgery or have donated blood within 12 weeks prior to the start of<br>       the study,<br><br>     - Who have taken any prescribed or over the counter drug (including antacid drug), with<br>       the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first<br>       dose administration,<br><br>     - Who have any clinical condition or prior therapy which, in the opinion of the<br>       Investigator, made the subject unsuitable for the study,<br><br>     - Who participated to any clinical trial with an investigational drug in the past 3<br>       months preceding study entry.<br>   ;<br>    Inclusion Criteria:<br><br>     - Male healthy volunteers 18 to 45 years of age,<br><br>     - All subjects to be of sub-Saharan African origins with both parents of sub-Saharan<br>       African origins too,<br><br>     - Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m)2<br>       from 18 to 28 kg/m2 inclusive at screening,<br><br>     - Able to communicate well with the Investigator and research staff and to comply with<br>       the requirements of the entire study,<br><br>     - Provision of written informed consent to participate as shown by a signature on the<br>       volunteer consent form,<br><br>     - Light smokers (less than 10 cigarettes per day) or subjects who are non-smokers. No<br>       smoking (or use of smoking substitute e.g. nicotine patch) is permitted from screening<br>       throughout the study,<br><br>     - Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not<br>       clinically significant by the principal Investigator. These will be measured after<br>       resting for 5 min,<br><br>     - Registered with the French Social Security in agreement with the French law on<br>       biomedical experimentation.<br><br>    Exclusion Criteria:<br><br>     - Who on direct questioning and physical examination have evidence of any clinically<br>       significant acute or chronic disease, including known or suspected HIV, HBV or HCV<br>       infection,<br><br>     - With any clinically significant abnormality following review of pre-study laboratory<br>       tests(ASAT, ALAT and alkaline phosphatase (ALP) must be within normal ranges), vital<br>       signs, full physical examination and ECG,<br><br>     - Who are within the exclusion period defined in the National Register for Healthy<br>       Volunteers of the French Ministry of Health,<br><br>     - Who forfeit their freedom by administrative or legal award or who were under<br>       guardianship,<br><br>     - Unwilling to give their informed consent,<br><br>     - Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or<br>       anti-HIV 1/2 or anti-HCV antibodies<br><br>     - Who have a history of allergy, intolerance or photosensitivity to any drug,<br><br>     - Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to<br>       any drug,<br><br>     - Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per<br>       week, one unit = 8 g or about 10 mL of pure alcohol),<br><br>     - Who drink more than 8 cups daily of beverage containing caffeine,<br><br>     - Who have a positive laboratory test for urine drug screening (opiates,<br>       cocaine,amphetamine, cannabis, benzodiazepines),<br><br>     - Who have undergone surgery or have donated blood within 12 weeks prior to the start of<br>       the study,<br><br>     - Who have taken any prescribed or over the counter drug (including antacid drug), with<br>       the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first<br>       dose administration,<br><br>     - Who have any clinical condition or prior therapy which, in the opinion of the<br>       Investigator, made the subject unsuitable for the study,<br><br>     - Who participated to any clinical trial with an investigational drug in the past 3<br>       months preceding study entry.<br>   ;<br>    Inclusion Criteria:<br><br>     - Male healthy volunteers 18 to 45 years of age,<br><br>     - All subjects to be of sub-Saharan African origins with both parents of sub-Saharan<br>       African origins too,<br><br>     - Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m)2<br>       from 18 to 28 kg/m2 inclusive at screening,<br><br>     - Able to communicate well with the Investigator and research staff and to comply with<br>       the requirements of the entire study,<br><br>     - Provision of written informed consent to participate as shown by a signature on the<br>       volunteer consent form,<br><br>     - Light smokers (less than 10 cigarettes per day) or subjects who are non-smokers. No<br>       smoking (or use of smoking substitute e.g. nicotine patch) is permitted from screening<br>       throughout the study,<br><br>     - Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not<br>       clinically significant by the principal Investigator. These will be measured after<br>       resting for 5 min,<br><br>     - Registered with the French Social Security in agreement with the French law on<br>       biomedical experimentation.<br><br>    Exclusion Criteria:<br><br>     - Who on direct questioning and physical examination have evidence of any clinically<br>       significant acute or chronic disease, including known or suspected HIV, HBV or HCV<br>       infection,<br><br>     - With any clinically significant abnormality following review of pre-study laboratory<br>       tests(ASAT, ALAT and alkaline phosphatase (ALP) must be within normal ranges), vital<br>       signs, full physical examination and ECG,<br><br>     - Who are within the exclusion period defined in the National Register for Healthy<br>       Volunteers of the French Ministry of Health,<br><br>     - Who forfeit their freedom by administrative or legal award or who were under<br>       guardianship,<br><br>     - Unwilling to give their informed consent,<br><br>     - Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or<br>       anti-HIV 1/2 or anti-HCV antibodies<br><br>     - Who have a history of allergy, intolerance or photosensitivity to any drug,<br><br>     - Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to<br>       any drug,<br><br>     - Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per<br>       week, one unit = 8 g or about 10 mL of pure alcohol),<br><br>     - Who drink more than 8 cups daily of beverage containing caffeine,<br><br>     - Who have a positive laboratory test for urine drug screening (opiates,<br>       cocaine,amphetamine, cannabis, benzodiazepines),<br><br>     - Who have undergone surgery or have donated blood within 12 weeks prior to the start of<br>       the study,<br><br>     - Who have taken any prescribed or over the counter drug (including antacid drug), with<br>       the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first<br>       dose administration,<br><br>     - Who have any clinical condition or prior therapy which, in the opinion of the<br>       Investigator, made the subject unsuitable for the study,<br><br>     - Who participated to any clinical trial with an investigational drug in the past 3<br>       months preceding study entry.<br>   ;<br>    Inclusion Criteria:<br><br>     - Male healthy volunteers 18 to 45 years of age,<br><br>     - All subjects to be of sub-Saharan African origins with both parents of sub-Saharan<br>       African origins too,<br><br>     - Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m)2<br>       from 18 to 28 kg/m2 inclusive at screening,<br><br>     - Able to communicate well with the Investigator and research staff and to comply with<br>       the requirements of the entire study,<br><br>     - Provision of written informed consent to participate as shown by a signature on the<br>       volunteer consent form,<br><br>     - Light smokers (less than 10 cigarettes per day) or subjects who are non-smokers. No<br>       smoking (or use of smoking substitute e.g. nicotine patch) is permitted from screening<br>       throughout the study,<br><br>     - Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not<br>       clinically significant by the principal Investigator. These will be measured after<br>       resting for 5 min,<br><br>     - Registered with the French Social Security in agreement with the French law on<br>       biomedical experimentation.<br><br>    Exclusion Criteria:<br><br>     - Who on direct questioning and physical examination have evidence of any clinically<br>       significant acute or chronic disease, including known or suspected HIV, HBV or HCV<br>       infection,<br><br>     - With any clinically significant abnormality following review of pre-study laboratory<br>       tests(ASAT, ALAT and alkaline phosphatase (ALP) must be within normal ranges), vital<br>       signs, full physical examination and ECG,<br><br>     - Who are within the exclusion period defined in the National Register for Healthy<br>       Volunteers of the French Ministry of Health,<br><br>     - Who forfeit their freedom by administrative or legal award or who were under<br>       guardianship,<br><br>     - Unwilling to give their informed consent,<br><br>     - Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or<br>       anti-HIV 1/2 or anti-HCV antibodies<br><br>     - Who have a history of allergy, intolerance or photosensitivity to any drug,<br><br>     - Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to<br>       any drug,<br><br>     - Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per<br>       week, one unit = 8 g or about 10 mL of pure alcohol),<br><br>     - Who drink more than 8 cups daily of beverage containing caffeine,<br><br>     - Who have a positive laboratory test for urine drug screening (opiates,<br>       cocaine,amphetamine, cannabis, benzodiazepines),<br><br>     - Who have undergone surgery or have donated blood within 12 weeks prior to the start of<br>       the study,<br><br>     - Who have taken any prescribed or over the counter drug (including antacid drug), with<br>       the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first<br>       dose administration,<br><br>     - Who have any clinical condition or prior therapy which, in the opinion of the<br>       Investigator, made the subject unsuitable for the study,<br><br>     - Who participated to any clinical trial with an investigational drug in the past 3<br>       months preceding study entry.<br>   ",,"Trypanosomiasis, African;Trypanosomiasis, African;Trypanosomiasis, African;Trypanosomiasis, African","Drug: Tablets Fexinidazole;Drug: Placebo;Drug: Tablets Fexinidazole;Drug: Placebo;Drug: Tablets Fexinidazole;Drug: Placebo;Drug: Tablets Fexinidazole;Drug: Placebo",,,DNDiFEX003,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT00982904,"16 December 2017","Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole","Randomized, Double-blind, Placebo-controlled Study of the Tolerability, and Pharmacokinetics of Fexinidazole After Single and Repeated Oral Ascending Doses, Completed by a Comparative Bioavailability Study of an Oral Suspension Versus a Tablet and an Exploratory Assessment of Food Effect, in Healthy Male Volunteers",,"Drugs for Neglected Diseases",22/09/2009,"  20090922","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00982904,"Not recruiting",No,"18 Years","45 Years",Male,01/09/2009,108,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator). ","Phase 1",France;France;France;France;France," ; ; ; ; ; ; ; ; ; ","Lionel Hovsepian, MD;Nathalie Strub-Wourgaft, MD;Lionel Hovsepian, MD;Nathalie Strub-Wourgaft, MD;Lionel Hovsepian, MD;Nathalie Strub-Wourgaft, MD;Lionel Hovsepian, MD;Nathalie Strub-Wourgaft, MD;Lionel Hovsepian, MD;Nathalie Strub-Wourgaft, MD",,;;;;;;;;;,;;;;;;;;;,"SGS Aster;Drugs for Neglected Diseases initiative;SGS Aster;Drugs for Neglected Diseases initiative;SGS Aster;Drugs for Neglected Diseases initiative;SGS Aster;Drugs for Neglected Diseases initiative;SGS Aster;Drugs for Neglected Diseases initiative","<br>    Inclusion Criteria:<br><br>     - All subjects to be of sub-Saharan African origins with both parents of sub-Saharan<br>       African origins too,<br><br>     - Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m2)<br>       from 18 to 28 kg/m2 at screening,<br><br>     - Able to communicate well with the Investigator and research staff and to comply with<br>       the requirements of the entire study,<br><br>     - Provision of written informed consent to participate as shown by a signature on the<br>       volunteer consent form,<br><br>     - Light smokers (less than 5 cigarettes per day) or subjects who are non-smokers.<br><br>     - Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not<br>       clinically significant by the principal Investigator.<br><br>     - Registered with the French Social Security in agreement with the French law on<br>       biomedical experimentation.<br><br>    Exclusion Criteria:<br><br>     - Who on direct questioning and physical examination have evidence of any clinically<br>       significant acute or chronic disease, including known or suspected HIV, HBV or HCV<br>       infection,<br><br>     - Who previously received fexinidazole,<br><br>     - With any clinically significant abnormality following review of pre-study laboratory<br>       tests(ASAT, ALAT and ALP must be within normal ranges), vital signs, full physical<br>       examination and ECG,<br><br>     - Who are within the exclusion period defined in the National Register for Healthy<br>       Volunteers of the French Ministry of Health,<br><br>     - Who forfeit their freedom by administrative or legal award or who were under<br>       guardianship,<br><br>     - Unwilling to give their informed consent,<br><br>     - Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or<br>       anti-HIV 1/2 or anti- HCV antibodies<br><br>     - Who have a history of allergy, intolerance or photosensitivity to any drug,<br><br>     - Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to<br>       any drug,<br><br>     - Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per<br>       week, one unit = 8 g or about 10 mL of pure alcohol),<br><br>     - Who drink more than 8 cups daily of beverage containing caffeine,<br><br>     - Who have a positive laboratory test for urine drug screening<br><br>     - Who have undergone surgery or have donated blood within 12 weeks prior to the start of<br>       the study,<br><br>     - Who have taken any prescribed or over the counter drug (including antacid drug), with<br>       the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first<br>       dose administration,<br><br>     - Who have any clinical condition or prior therapy which, in the opinion of the<br>       Investigator, made the subject unsuitable for the study,<br><br>     - Who participated to any clinical trial with an investigational drug in the past 3<br>       months preceding study entry.<br>   ;<br>    Inclusion Criteria:<br><br>     - All subjects to be of sub-Saharan African origins with both parents of sub-Saharan<br>       African origins too,<br><br>     - Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m2)<br>       from 18 to 28 kg/m2 at screening,<br><br>     - Able to communicate well with the Investigator and research staff and to comply with<br>       the requirements of the entire study,<br><br>     - Provision of written informed consent to participate as shown by a signature on the<br>       volunteer consent form,<br><br>     - Light smokers (less than 5 cigarettes per day) or subjects who are non-smokers.<br><br>     - Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not<br>       clinically significant by the principal Investigator.<br><br>     - Registered with the French Social Security in agreement with the French law on<br>       biomedical experimentation.<br><br>    Exclusion Criteria:<br><br>     - Who on direct questioning and physical examination have evidence of any clinically<br>       significant acute or chronic disease, including known or suspected HIV, HBV or HCV<br>       infection,<br><br>     - Who previously received fexinidazole,<br><br>     - With any clinically significant abnormality following review of pre-study laboratory<br>       tests(ASAT, ALAT and ALP must be within normal ranges), vital signs, full physical<br>       examination and ECG,<br><br>     - Who are within the exclusion period defined in the National Register for Healthy<br>       Volunteers of the French Ministry of Health,<br><br>     - Who forfeit their freedom by administrative or legal award or who were under<br>       guardianship,<br><br>     - Unwilling to give their informed consent,<br><br>     - Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or<br>       anti-HIV 1/2 or anti- HCV antibodies<br><br>     - Who have a history of allergy, intolerance or photosensitivity to any drug,<br><br>     - Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to<br>       any drug,<br><br>     - Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per<br>       week, one unit = 8 g or about 10 mL of pure alcohol),<br><br>     - Who drink more than 8 cups daily of beverage containing caffeine,<br><br>     - Who have a positive laboratory test for urine drug screening<br><br>     - Who have undergone surgery or have donated blood within 12 weeks prior to the start of<br>       the study,<br><br>     - Who have taken any prescribed or over the counter drug (including antacid drug), with<br>       the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first<br>       dose administration,<br><br>     - Who have any clinical condition or prior therapy which, in the opinion of the<br>       Investigator, made the subject unsuitable for the study,<br><br>     - Who participated to any clinical trial with an investigational drug in the past 3<br>       months preceding study entry.<br>   ;<br>    Inclusion Criteria:<br><br>     - All subjects to be of sub-Saharan African origins with both parents of sub-Saharan<br>       African origins too,<br><br>     - Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m2)<br>       from 18 to 28 kg/m2 at screening,<br><br>     - Able to communicate well with the Investigator and research staff and to comply with<br>       the requirements of the entire study,<br><br>     - Provision of written informed consent to participate as shown by a signature on the<br>       volunteer consent form,<br><br>     - Light smokers (less than 5 cigarettes per day) or subjects who are non-smokers.<br><br>     - Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not<br>       clinically significant by the principal Investigator.<br><br>     - Registered with the French Social Security in agreement with the French law on<br>       biomedical experimentation.<br><br>    Exclusion Criteria:<br><br>     - Who on direct questioning and physical examination have evidence of any clinically<br>       significant acute or chronic disease, including known or suspected HIV, HBV or HCV<br>       infection,<br><br>     - Who previously received fexinidazole,<br><br>     - With any clinically significant abnormality following review of pre-study laboratory<br>       tests(ASAT, ALAT and ALP must be within normal ranges), vital signs, full physical<br>       examination and ECG,<br><br>     - Who are within the exclusion period defined in the National Register for Healthy<br>       Volunteers of the French Ministry of Health,<br><br>     - Who forfeit their freedom by administrative or legal award or who were under<br>       guardianship,<br><br>     - Unwilling to give their informed consent,<br><br>     - Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or<br>       anti-HIV 1/2 or anti- HCV antibodies<br><br>     - Who have a history of allergy, intolerance or photosensitivity to any drug,<br><br>     - Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to<br>       any drug,<br><br>     - Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per<br>       week, one unit = 8 g or about 10 mL of pure alcohol),<br><br>     - Who drink more than 8 cups daily of beverage containing caffeine,<br><br>     - Who have a positive laboratory test for urine drug screening<br><br>     - Who have undergone surgery or have donated blood within 12 weeks prior to the start of<br>       the study,<br><br>     - Who have taken any prescribed or over the counter drug (including antacid drug), with<br>       the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first<br>       dose administration,<br><br>     - Who have any clinical condition or prior therapy which, in the opinion of the<br>       Investigator, made the subject unsuitable for the study,<br><br>     - Who participated to any clinical trial with an investigational drug in the past 3<br>       months preceding study entry.<br>   ;<br>    Inclusion Criteria:<br><br>     - All subjects to be of sub-Saharan African origins with both parents of sub-Saharan<br>       African origins too,<br><br>     - Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m2)<br>       from 18 to 28 kg/m2 at screening,<br><br>     - Able to communicate well with the Investigator and research staff and to comply with<br>       the requirements of the entire study,<br><br>     - Provision of written informed consent to participate as shown by a signature on the<br>       volunteer consent form,<br><br>     - Light smokers (less than 5 cigarettes per day) or subjects who are non-smokers.<br><br>     - Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not<br>       clinically significant by the principal Investigator.<br><br>     - Registered with the French Social Security in agreement with the French law on<br>       biomedical experimentation.<br><br>    Exclusion Criteria:<br><br>     - Who on direct questioning and physical examination have evidence of any clinically<br>       significant acute or chronic disease, including known or suspected HIV, HBV or HCV<br>       infection,<br><br>     - Who previously received fexinidazole,<br><br>     - With any clinically significant abnormality following review of pre-study laboratory<br>       tests(ASAT, ALAT and ALP must be within normal ranges), vital signs, full physical<br>       examination and ECG,<br><br>     - Who are within the exclusion period defined in the National Register for Healthy<br>       Volunteers of the French Ministry of Health,<br><br>     - Who forfeit their freedom by administrative or legal award or who were under<br>       guardianship,<br><br>     - Unwilling to give their informed consent,<br><br>     - Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or<br>       anti-HIV 1/2 or anti- HCV antibodies<br><br>     - Who have a history of allergy, intolerance or photosensitivity to any drug,<br><br>     - Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to<br>       any drug,<br><br>     - Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per<br>       week, one unit = 8 g or about 10 mL of pure alcohol),<br><br>     - Who drink more than 8 cups daily of beverage containing caffeine,<br><br>     - Who have a positive laboratory test for urine drug screening<br><br>     - Who have undergone surgery or have donated blood within 12 weeks prior to the start of<br>       the study,<br><br>     - Who have taken any prescribed or over the counter drug (including antacid drug), with<br>       the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first<br>       dose administration,<br><br>     - Who have any clinical condition or prior therapy which, in the opinion of the<br>       Investigator, made the subject unsuitable for the study,<br><br>     - Who participated to any clinical trial with an investigational drug in the past 3<br>       months preceding study entry.<br>   ",,"Human African Trypanosomiasis;Human African Trypanosomiasis;Human African Trypanosomiasis;Human African Trypanosomiasis","Drug: Fexinidazole/Placebo;Drug: Fexinidazole/Placebo;Drug: Fexinidazole/Placebo;Drug: Fexinidazole/Placebo","Occurence of adverse events (AEs);Occurence of adverse events (AEs);Occurence of adverse events (AEs)","Pharmacokinetic : measure of blood and urine concentration of fexinidazole, fexinidazole sulfoxide and fexinidazole sulfone in order to determine AUC0-t and Cmax values, for all dose levels",DNDiFEX001,"Please refer to primary and secondary sponsors",Sanofi,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT00906880,"19 February 2015","Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase","Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Stage",NECT-FIELD,"Drugs for Neglected Diseases",19/05/2009,"  20090519","10/13/2025 15:57:23",ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00906880,"Not recruiting",No,N/A,N/A,Both,01/04/2009,630,Interventional,"Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment","Phase 4",Congo," ; ","Johannes Blum, MD;Victor Kande, MD",,;,;,"Swiss Tropical & Public Health Institute;PNLTHA-DRC;","<br>    Inclusion Criteria:<br><br>    All patients diagnosed as stage 2 HAT according to the diagnostic protocols in use at the<br>    treatment center (generally, if presence of parasites in blood, lymph node fluid or CSF<br>    and an elevated white blood cell count in the CSF, but this can vary from center to<br>    center) will be included if a written Informed Consent is given by the patient or a<br>    legally acceptable representative if the patient is a minor or unable to communicate.<br><br>     - Pregnancy and breastfeeding women: On a case by case basis according to the<br>       guidelines of the National HAT Control Programme or the NGO, the Investigator will<br>       decide to treat the patient or to defer the treatment. In case of inclusion, the<br>       mother-child pairs or the children of lactating mothers will be closely monitored<br>       during treatment and follow up.<br><br>     - Children under 2 years of age: On a case by case basis, the Investigator will decide<br>       to treat an infant with NECT or an alternative treatment (preferably eflornithine).<br>       In case of inclusion, these infants will be closely monitored during treatment and<br>       follow up like all children less than 12 years of age.<br><br>    Exclusion Criteria:<br><br>     - Unable to take oral medication, and impossibility to use a nasogastric tube.<br><br>     - Treatment failure after nifurtimox-eflornithine treatment.<br><br>     - Any other condition or reason for which the Investigator (or the responsible treating<br>       staff member) judges that another or no HAT treatment is warranted.<br>   ",,"Human African Trypanosomiasis","Drug: Nifurtimox-Eflronithine Combination Treatment (NECT)","Proportion of patients discharged alive from the hospital or the treatment center","Incidence of serious AE (SAE) and severe AE (CTC score 3 and 4) related to treatment, and overall frequency and nature of AE and need for additional medications to manage these.;Effectiveness: The clinical cure rate (Survival without clinical and/or parasitological signs of HAT);Number of temporary treatment interruptions, number of premature treatment cessations, length of hospitalization stay (including observation period), treatment compliance (deviation in dosing), and other feasibility indicators.",HAT0208,"Please refer to primary and secondary sponsors","Ministry of Public Health, Democratic Republic of the Congo;Swiss Tropical & Public Health Institute",,,,,,,,,,,,,,,,,,,No,False,"          "
ISRCTN03148609,"14 January 2019","Clinical study comparing the nifurtimox-eflornithine combination with the standard eflornithine regimen for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis in the meningo-encephalitic phase","Clinical study comparing the nifurtimox-eflornithine combination with the standard eflornithine regimen for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis in the meningo-encephalitic phase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",,"UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)",18/04/2008,"  20080418","10/13/2025 15:57:23",ISRCTN,http://isrctn.com/ISRCTN03148609,"Not Recruiting",No,,,Both,01/11/2005,280,Interventional,"Randomised, open label, clinical non-inferiority trial (Treatment)","Not Specified",Uganda,,,,,,,"Inclusion criteria: <br>        1. Confirmed second-stage Tb gambiense infection: presence of the parasite in blood, lymph node fluid or cerebrospinal fluid (CSF) and greater than 20 white blood cells/µL in CSF<br>        2. Age 15 years or older, either sex<br>        3. Resident in a radius of 50 km from Omugo Sleeping Sickness Treatment Centre<br>        4. Written informed consent of the patient or of a legally acceptable representative if the patient is a minor (less than 18 years for both genders in Uganda) or unable to communicate<br>      ","Exclusion criteria: <br>        1. Pregnant woman (systematic testing (urine human chorionic gonadotropin [HCG]) of women of childbearing potential)<br>        2. Treated for late-stage HAT during the last 36 months. Patients previously treated for first-stage (pentamidine) can be included.<br>        3. Unlikely to have access to the treatment centre or be accessible at their place of residence for 18 months after treatment<br>        4. Unable to take oral medication<br>        5. Suffering from conditions other than second stage HAT that seriously limit the chances of survival over 18 months time<br>        6. Severe anaemia (haemoglobin [Hb] less than 5 g/dl)<br>        7. Severe underlying diseases upon admission (e.g. active tuberculosis and/or being treated for TB; bacterial or cryptoccocal meningitis; stages 3 or 4 human immunodeficiency virus [HIV]/acquired immune deficiency syndrome [AIDS] according to the WHO clinical definition) (WHO, 1986)<br>        8. Renal failure based on clinical examination combined with biochemistry. Calculated creatinine clearance less than 20 mL/min (Cockcroft's equation).<br>        8.1. Males: creatinine clearance (mL/min) = (Wt [kg] x 140 - age [years]) ÷ (72 x serum creatinine [mg/dL])<br>        8.2. Females: 0.85 x the above value<br>        9. Hepatic failure based on clinical examination combined with biochemistry total bilirubin greater than 50 µmol/L, alanine aminotransferase (ALAT)/glutamate pyruvate transaminase [GPT] greater than 70 UI/L<br>      ","Human African trypanosomiasis <br>Infections and Infestations <br>African trypanosomiasis ","<br>        1. Eflornithine IV 7 days 400 mg/kg/day 12 hourly and nifurtimox orally 10 days 15 mg/kg/day 8 hourly<br>        2. Eflornithine IV 14 days 400 mg/kg/day 6 hourly<br><br>        The total duration of follow up is 18 months for both arms.<br><br>        Contact details for Principal Investigators:<br>        1. Moyo site:<br>        Dr Seraphine Adibaku<br>        District Director of Health Services<br>        Moyo District Local Government<br>        P.O. Box 1<br>        Moyo, Uganda<br><br>        2. Omugo site:<br>        Dr Freddie Kagwisagi Kansiime<br>        Deputy Director<br>        Coordinating Office for Control of Trypanosomiasis in Uganda (COCTU)<br>        P.O. Box 16345<br>        Kampala, Uganda<br>","The cure rate assessed via the number of alive subjects 18 months after treatment without laboratory signs of infection, i.e. absence of trypanosome(s) in the CSF, blood or lymph node fluid and CSF leukocytes count less than 20/µl. ","<br>        1. The duration of survival without laboratory signs of infection up to 18 months after  treatment<br>        2. Proportion of serious adverse events and of major (grade 3 and 4) adverse events related to the treatment (adverse occurring in each treatment arm)<br>      ","WHO ref: A50402 and A60444; NFE0105; NFE0206","United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)",,,01/01/1990,,"          Ethics approval received from:          1. Ethical Clearance Committee (Uganda) on the 8th May 2005 and 8th May 2006 (ref: VCD/UNCT/06)          2. World Health Organization (WHO) Ethics Review Committee (ERC) on the 30th May 2005, and was reviewed on the 26th April 2006 and 27th February 2007        ",,,Yes,,,,13/06/2009,,"1. 2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/29471865",,,,"Not provided at time of registration","Not provided at time of registration",No,False,"          "
ISRCTN55042030,"1 March 2021","Assessing three day pentamidine for first stage human african trypanosomiasis in Uganda","Assessing three day pentamidine for first stage human african trypanosomiasis in Uganda                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",,"UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)",14/12/2007,"  20071214","10/13/2025 15:57:23",ISRCTN,http://isrctn.com/ISRCTN55042030,"Not Recruiting",No,,,Both,01/12/2007,440,Interventional,"Non-inferiority clinical trial (Treatment)","Not Specified",Uganda,,,,,,,"Inclusion criteria: <br>        1. Age greater than or equal to 10 years and less than 60 years<br>        2. Trypanosome positive lymph node aspirate or blood<br>        3. Consenting patient<br>        4. Alternative diagnoses excluded by appropriate clinical and laboratory investigations<br>      ","Exclusion criteria: <br>        1. Abnormal Cerebrospinal Fluid (CSF):<br>        1.1. CSF White Blood Cell [WBC] count greater than 5 WBC/µl<br>        1.2. Presence of trypanosomes<br>        1.3. Haemorrhagic CSF<br>        2. Pregnant<br>        3. Previous HAT treatment<br>        4. Known allergy or reaction to pentamidine<br>        5. Diabetes mellitus<br>        6. Severe difficulty expected with follow-up. Follow-up is difficult for all patients; only if it appears very probable that a patient will not be able to present for follow-up examinations until 18 months post-treatment should he/she be excluded (e.g. Sudanese refugees who have enrolled in the ongoing voluntary repatriation programme)<br>        7. Patients with severe chronic conditions for whom the chance of survival until the end of the 18 months follow-up period is doubtful (e.g. clinical Human Immunodeficiency Virus [HIV]/Acquired Immune Deficiency Syndrome [AIDS] stage IV and Tuberculosis)<br>      ","Human African Trypanosomiasis (HAT) <br>Infections and Infestations <br>Human African Trypanosomiasis","<br>        1. Three days pentamidine IM at a dose of 4 mg/kg/day<br>        2. Seven days pentamidine IM at a dose of 4 mg/kg/day<br><br>        Contact details for Principal Investigator:<br>        Dr Jimmy Opigo<br>        District Directorate of Health Services<br>        Moyo District Local Government<br>        P.O. Box 1<br>        Moyo, Uganda<br>        Tel: +256 (0)37 2273721<br>        Moblie: +256 (0)77 2962601<br>        Email: opigojimmy@gmail.com<br>","Proportion of cases with favourable evolution at 6 months post-treatment, based on laboratory results.","<br>        1. Proportion of cases with favourable evolution at the end of treatment assessment (day 10), 3 and 12 months post-treatment, based on laboratory results<br>        2. Cure rate at 18 months post-treatment, based on laboratory results<br>        3. Frequency and severity of adverse events<br>      ","A60914; HAT PDE 06-02","United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)",,,01/01/1900,"          Ethics approval received from:          1. Ethical Clearance Committee (Uganda) on the 8th December 2006 (ref: VCD/UNCT 08 12 06)          2. World Health Organization (WHO) Ethics Review Committee (ERC) on the 18th July 2007 (ref: A60914)        ",,,,Yes,,,,30/06/2011,,"2009 results in https://pubmed.ncbi.nlm.nih.gov/19559477/ (added 18/02/2021)",,,,"Not provided at time of registration","Not provided at time of registration",No,False,"          "
NCT00489658,"19 February 2015","Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda","Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda",NECS,Epicentre,20/06/2007,"  20070620","10/13/2025 15:57:23",ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00489658,"Not recruiting",No,N/A,N/A,Both,01/10/2002,31,Interventional,"Intervention Model: Single Group Assignment, Masking: Open Label","Phase 2/Phase 3",Uganda," ; ","Patrice Piola, MD MSc;Gerardo Priotto, MD MPH",,;,;,Epicentre;Epicentre,"<br>    Inclusion Criteria:<br><br>     - Stage 2 infection with Trypanosoma brucei gambiense diagnosed within the previous 14<br>       days, as defined by either of the following: (i) Presence of trypanosomes in blood or<br>       lymph node fluid and WBC count in CSF > 5 / mm3, or (ii) Presence of trypanosomes in<br>       the CSF with any CSF WBC count<br><br>     - Residence in the study area<br><br>     - Written informed consent (to be obtained from parent/guardian for children under 18<br>       years and patients with impaired cognition)<br><br>    Exclusion Criteria:<br><br>     - Pregnancy or clinical history suggestive thereof<br><br>     - Weight < 10 Kg<br><br>     - History of any HAT treatment within the previous 24 months<br><br>     - Inability to undergo hospitalisation or attend follow-up visits during the 24 months<br>       following discharge<br><br>     - Severe anemia (Hb< 5g/dl)<br><br>     - Active tuberculosis (sputum positive)<br><br>     - HIV positive (if patient has been tested and results are known)<br><br>     - Severe renal or hepatic failure<br><br>     - Bacterial or cryptococcal meningitis<br><br>     - Other severe underlying diseases upon admission<br><br>     - Refugee status<br>   ",,"Trypanosomiasis, African","Drug: Eflornithine plus Nifurtimox combination therapy","Treatment failure (death within 30 days of inclusion, or later if judged as related to Human African trypanosomiasis; termination of treatment due to adverse events; evidence of infection relapse at or after discharge, up to 24 months post discharge)","Occurrence and severity of serious clinically apparent adverse events;Occurrence and severity of biochemical (ALAT, creatinine, bilirubin) and haematological (abnormal total and differential leukocyte count, haemoglobin) adverse events",NECS,"Please refer to primary and secondary sponsors","Medecins Sans Frontieres",,,,,,,,,,,,,,,,,,,No,False,"          "
NCT00330148,"19 February 2015","Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis","Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase",,Epicentre,24/05/2006,"  20060524","10/13/2025 15:57:23",ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT00330148,"Not recruiting",No,N/A,N/A,Both,01/03/2001,435,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment","Phase 3",Uganda," ","Gerardo Priotto, MD, MPH",,,,Epicentre,"<br>    Inclusion Criteria:<br><br>     - confirmed second-stage T.b. gambiense infection :<br><br>        - Infection diagnosed parasitologically (blood or lymph node fluid) and white<br>         blood cells > 5/mm3 in cerebrospinal fluid (CSF)<br><br>        - or Trypanosomes detected in the CSF with any CSF cell count<br><br>     - and resident in the district<br><br>     - and written consent of the patient or of one of the parents/guardians for children<br>       under 15 years of age.<br><br>    Exclusion Criteria:<br><br>     - Trypanosome absent from blood (or lymph node fluid) and from CSF<br><br>     - Or women pregnant on inclusion<br><br>     - Or previous history of HAT confirmed treated during the last 24 months<br><br>     - Or impossibility of regular access to the treatment centre during the 2 years<br>       following the end of the treatment<br><br>     - Or less than 10 kg of body weight<br><br>     - Or refugee patient<br>   ",,"Trypanosomiasis, African","Drug: melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;Drug: melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;Drug: nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d","Cure rate","Adverse events temporally associated with the treatment;Major adverse events temporally associated with the treatment",EPICENTRE-BTT,"Please refer to primary and secondary sponsors","Medecins Sans Frontieres;Embassy of France in Uganda;National Sleeping Sickness Control Program, Uganda",,,,,,,,,,,,,,,,,,,No,False,"          "
ISRCTN36877262,"13 January 2015","Clinical study on alternative treatment of patients with second stage Trypanosoma brucei gambiense sleeping sickness","                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ",,"Institute of Tropical Medicine (Belgium)",16/12/2005,"  20051216","10/13/2025 15:57:23",ISRCTN,http://isrctn.com/ISRCTN36877262,"Not Recruiting",No,,,Both,01/02/1998,600,Interventional,"An open randomised trial was designed to test equivalence between standard melarsoprol and 3 other regimens. (Treatment)",,"Congo, Democratic Republic",,,,,,,"Inclusion criteria: 1, Older than 15 years<br>2. Second-stage parasitologically confirmed T. b. gambiense infection<br>3. Never previously treated for sleeping sickness<br><br>Second stage disease was defined as: 1° cerebrospinal fluid (CSF) white blood cell (WBC) count >20 /µl and detectable IgM in the CSF; or 2° trypanosomes detected in CSF.","Exclusion criteria: 1. Glasgow coma scale <8<br>2. Pregnancy<br>3. Active tuberculosis<br>4. Positive syphilis serology<br>5. Bacterial or cryptococcal meningitis<br>6. Severe anaemia<br>7. Severe renal or hepatic dysfunction<br>8. Hemorrhagic CSF<br>9. Residence beyond 100 km from Bwamanda Hospital","Trypanosoma brucei gambiense Human African Trypanosomiasis in second stage <br>Infections and Infestations <br>African trypanosomiasis","A. Standard melarsoprol as administered in the DRC: 3 series of 3.6 mg/kg/day intravenously (IV) (maximum 180 mg/day) for 3 days with 7-day breaks in between series. Total dose: 32.4 mg/kg.<br><br>B. Concise, consecutive lower-dose melarsoprol: IV during 10 days (0.6 mg/kg on day 1; 1.2 mg/kg on day 2; 1.8 mg/kg from days 3 to 10; maximum 90 mg/day). Total dose: 16.2 mg/kg.<br><br>C. Nifurtimox monotherapy: orally, under nurse supervision, 5 mg/kg every 8 hours for 14 days. Total dose: 210 mg/kg.<br><br>D. Low-dose concise, consecutive melarsoprol-nifurtimox combination: 2 days melarsoprol alone (0.6 mg/kg on day 1; 1.2 mg/kg on day 2) followed by 8 days 7.5 mg/kg nifurtimox every 12 hours combined with melarsoprol 1.2 mg/kg/day. Total melarsoprol dose: 11.4 mg/kg. Total nifurtimox dose: 120 mg/kg.","Primary outcomes were relapse, severe adverse events and death attributed to treatment.","Secondary outcomes were frequency of other adverse events",N/A,"Institute of Tropical Medicine (Belgium), Belgian Directorate-General for Development Co-operation (Belgium)",,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT00146627,"10 October 2016","Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis","Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase",,"Drugs for Neglected Diseases",06/09/2005,"  20050906","10/13/2025 15:57:23",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00146627,"Not recruiting",No,"15 Years","70 Years",Both,01/09/2004,280,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment","Phase 3","Congo, The Democratic Republic of the;Congo;Congo, The Democratic Republic of the;The Democratic Republic of the Congo;Uganda;Congo, The Democratic Republic of the;Congo;Congo, The Democratic Republic of the;The Democratic Republic of the Congo;Uganda"," ; ; ; ","Els Torreele, PhD;Gerardo Priotto, MD, MPH;Els Torreele, PhD;Gerardo Priotto, MD, MPH",,;;;,;;;,"Drugs for Neglected Diseases;Epicentre;Drugs for Neglected Diseases;Epicentre","<br>    Inclusion Criteria:<br><br>     - confirmed second-stage T.b. gambiense infection : presence of the parasite in blood,<br>       lymph node fluid or CSF and >20 white blood cells/µL in CSF. In presence of blood in<br>       the CSF, lumbar puncture must be done again or the patient cannot be included in the<br>       study (see 10.9.1).<br><br>     - and of age 15 years or older.<br><br>     - and resident in __________ (each site will define boundaries or maximum distance)<br><br>     - and written informed consent of the patient or of a legally acceptable representative<br>       if the patient is a minor (<18 years for both genders in Uganda and Angola, <18 years<br>       for males and <16 years for females in the Democratic Republic of Congo) or unable to<br>       communicate.<br><br>    Exclusion Criteria:<br><br>     - pregnant woman (systematic testing of women of childbearing potential)<br><br>     - treated for late-stage HAT during the last 36 months. Patients previously treated for<br>       first-stage (pentamidine) can be included.<br><br>     - unlikely to have access to the treatment centre or be accessible at their place of<br>       residence for 18 months after treatment<br><br>     - unable to take oral medication<br><br>     - suffering from conditions other than second stage HAT that seriously limit the<br>       chances of survival over 18 months time<br><br>     - Severe anemia (Hb< 5g/dl)<br><br>     - Severe underlying diseases upon admission (e.g. Active tuberculosis and/or being<br>       treated for TB; Bacterial or cryptococcal meningitis; Stages 3 or 4 HIV/AIDS<br>       according to the WHO clinical definition) (WHO, 1986).<br><br>     - Severe renal failure based on clinical examination combined with biochemistry if<br>       available: creatinine clearance <20mL/min<br><br>     - Severe hepatic failure based on clinical examination combined with biochemistry if<br>       available: total bilirubin >50 µmol/L, ALAT/GPT >70 UI/L, unless these laboratory<br>       values are determined by the investigator as likely due to conditions other than<br>       hepatic failure.<br>   ;<br>    Inclusion Criteria:<br><br>     - confirmed second-stage T.b. gambiense infection : presence of the parasite in blood,<br>       lymph node fluid or CSF and >20 white blood cells/µL in CSF. In presence of blood in<br>       the CSF, lumbar puncture must be done again or the patient cannot be included in the<br>       study (see 10.9.1).<br><br>     - and of age 15 years or older.<br><br>     - and resident in __________ (each site will define boundaries or maximum distance)<br><br>     - and written informed consent of the patient or of a legally acceptable representative<br>       if the patient is a minor (<18 years for both genders in Uganda and Angola, <18 years<br>       for males and <16 years for females in the Democratic Republic of Congo) or unable to<br>       communicate.<br><br>    Exclusion Criteria:<br><br>     - pregnant woman (systematic testing of women of childbearing potential)<br><br>     - treated for late-stage HAT during the last 36 months. Patients previously treated for<br>       first-stage (pentamidine) can be included.<br><br>     - unlikely to have access to the treatment centre or be accessible at their place of<br>       residence for 18 months after treatment<br><br>     - unable to take oral medication<br><br>     - suffering from conditions other than second stage HAT that seriously limit the<br>       chances of survival over 18 months time<br><br>     - Severe anemia (Hb< 5g/dl)<br><br>     - Severe underlying diseases upon admission (e.g. Active tuberculosis and/or being<br>       treated for TB; Bacterial or cryptococcal meningitis; Stages 3 or 4 HIV/AIDS<br>       according to the WHO clinical definition) (WHO, 1986).<br><br>     - Severe renal failure based on clinical examination combined with biochemistry if<br>       available: creatinine clearance <20mL/min<br><br>     - Severe hepatic failure based on clinical examination combined with biochemistry if<br>       available: total bilirubin >50 µmol/L, ALAT/GPT >70 UI/L, unless these laboratory<br>       values are determined by the investigator as likely due to conditions other than<br>       hepatic failure.<br>   ",,"Trypanosomiasis, African;Trypanosomiasis, African","Drug: Eflornithine;Drug: Nifurtimox;Drug: Eflornithine;Drug: Nifurtimox",,,"DNDi-HAT0105; Epicentre-NECT;DNDi-HAT0105; Epicentre-NECT","Please refer to primary and secondary sponsors;Please refer to primary and secondary sponsors","Medecins Sans Frontieres, Netherlands;PNLTHA-DRC;;PNLTHA-RoC;Epicentre;Swiss Tropical & Public Health Institute;World Health Organization;Medecins Sans Frontieres, Netherlands;PNLTHA-DRC;;PNLTHA-RoC;Epicentre;Swiss Tropical & Public Health Institute;World Health Organization",,,,,,,,,,,,,,,,,,,No,False,"          "
ISRCTN85534673,"17 October 2016","International randomized controlled phase III trial of DB289 versus pentamidine for the treatment of first stage Human African Trypanosomiasis (HAT)","International randomized controlled phase III trial of DB289 versus pentamidine for the treatment of first stage Human African Trypanosomiasis (HAT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ",,"Immtech Pharmaceuticals, Inc. (USA)",23/08/2005,"  20050823","10/13/2025 15:57:23",ISRCTN,http://isrctn.com/ISRCTN85534673,"Not Recruiting",No,,,Both,15/07/2005,250,Interventional,"Randomised controlled trial (Treatment)","Phase III",Angola;Congo;Sudan,,,,,,,"Inclusion criteria: 1. The patient has first stage T. b. gambiense infection, i.e. parasitologically confirmed infection in the blood or lymph node aspirate and White Blood Cell count (WBC) less than or equal to 5 mm^3 detected in the CerebroSpinal Fluid (CSF) by microscopic examination. <br>2. Patient is male or female 12 years of age or older and more than or equal to 30 kg.","Exclusion criteria: 1. The patient has possible or confirmed second stage T. b. gambiense infection, i.e. presence of parasite in the CSF upon microscopic examination or a WBC count in the CSF of more than 5 mm^-3<br>2. Active clinically relevant medical conditions that in the Investigator's opinion may jeopardise subject safety or interfere with participation in the study, including but not limited to: significant liver diseases, chronic pulmonary diseases, significant cardiovascular diseases, diabetes, thyroid diseases, gout, infection including known Human Immunodeficiency Virus (HIV) infection, Central Nervous System (CNS) trauma or seizure disorders<br>3. Coma Score of less than nine on the Glasgow Coma Scale","Human African Trypanosomiasis (HAT) or sleeping sickness <br>Infections and Infestations <br>Human African Trypanosomiasis (HAT)","The subjects will receive either DB289 or pentamidine treatment according to their randomisation.","The primary efficacy variable will be the combined rate of clinical and parasitological cure at the Test of Cure evaluation (12 month evaluation) in the Per Protocol dataset.","Parasitological cure, clinical cure, probable relapse, relapse and death rates at the End of Treatment and at the 3, 6, 18 and 24 month evaluations will also be determined.","289-C-010 (C05-010)","Bill and Melinda Gates Foundation (USA) - grant ref: 38381",,,,,,,,,,,,,,,,,,,,No,False,"          "
ISRCTN35617647,"13 January 2015","Assessing three day pentamidine for early stage human African trypanosomiasis (Angola)","                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ",,"UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)",07/06/2005,"  20050607","10/13/2025 15:57:23",ISRCTN,http://isrctn.com/ISRCTN35617647,"Not Recruiting",No,,,Both,20/12/2004,440,Interventional,"Randomised controlled trial (Treatment)",,Angola,,,,,,,"Inclusion criteria: 1. Aged more than or equal to 14 years and less than 60 years<br>2. Parasite positive (on examination of lymph juice, by Capillary Tube Centrifugation [CTC] or miniature Anion-Exchange Centrifugation [mAEC] on whole blood)<br>3. Alternative diagnoses excluded clinically and by appropriate laboratory investigations<br>4. Capable of and giving informed consent to the study","Exclusion criteria: 1. Stage II Human African Trypanosomiasis (HAT): defined as parasites in cerebrospinal fluid (CSF), or having more than or equal to 6 cells/mm^3 in CSF; or more than 100 red cells/mm^3 (""""bloody tap"""")<br>2. Pregnant<br>3. Previous HAT<br>4. Known allergy or reactions to pentamidine<br>5. Diabetes mellitus<br>6. Difficulty to comply with follow-up (patients of no fixed abode and refugees, for example)","Human African Trypanosomiasis (HAT) <br>Infections and Infestations <br>Human African Trypanosomiasis (HAT)","This will be an open, randomised comparison of two pentamidine treatment regimens, given over three days or seven days with a non-inferiority trial design.","Proportion of cases with favourable progress at 6 months, based on clinical state and laboratory status.","1. Proportion of cases with favourable progress at discharge, 3 and 12 months based on clinical state and laboratory status<br>2. Cure rate at 18 months, based on based on clinical state and laboratory status<br>3. Frequency and severity of adverse events",A30765,"United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)",,,,,,,,,,,,,,,,,,,,No,False,"          "
